Adamski, J., Price, A., Dive, C., & Makin, G. (2013). Hypoxia– induced cytotoxic drug resistance in osteosarcoma is independent of HIF-1Alpha. PloS one, 8(6), e65304. https://doi.org/10.1371/journal.pone.0065304

Adebambo, O. A., Shea, D., & Fry, R. C. (2018). Cadmium disrupts signaling of the hypoxia-inducible (HIF) and transforming growth factor (TGF-β) pathways in placental JEG-3 trophoblast cells via reactive oxygen species. Toxicology and applied pharmacology, 342, 108-115. https://doi.org/10.1016/j.taap.2018.01.010

Appelhoff, R. J., Tian, Y.-M., Raval, R. R., Turley, H., Harris, A. L., Pugh, C. W., Ratcliffe, P. J., & Gleadle, J. M. (2004). Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. Journal of Biological Chemistry, 279(37), 38458- 38465. https://doi.org/10.1074/jbc.M406026200

Bai, J., Chen, W.-B., Zhang, X.-Y., Kang, X.-N., Jin, L.-J., Zhang, H., & Wang, Z.-Y. (2020). HIF-2α regulates CD44 to promote cancer stem cell activation in triple-negative breast cancer via PI3K/AKT/mTOR signaling. World journal of stem cells, 12(1), 87-99. https://doi.org/10.4252/wjsc.v12.i1.87

Bailey, C. M., Liu, Y., Peng, G., Zhang, H., He, M., Sun, D., Zheng, P., Liu, Y., & Wang, Y. (2020). Liposomal formulation of HIF-1α inhibitor echinomycin eliminates established metastases of triple-negative breast cancer. Nanomedicine: Nanotechnology, Biology and Medicine, 29, 102278. https://doi.org/10.1016/j.nano.2020.102278

Balamurugan, K. (2016). HIF‐1 at the crossroads of hypoxia, inflammation, and cancer. International journal of cancer, 138(5), 1058-1066. https://doi.org/10.1002/ijc.29519

Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 444(7120), 756-760. https://doi.org/10.1038/nature05236

Barbone, D., Cheung, P., Battula, S., Busacca, S., Gray, S. G., Longley, D. B., Bueno, R., Sugarbaker, D. J., Fennell, D. A., & Broaddus, V. C. (2012). Vorinostat eliminates multicellular resistance of mesothelioma 3D spheroids via restoration of Noxa expression. PloS one, 7(12), e52753. https://doi.org/10.1371/journal.pone.0052753

Barsoum, I. B., Smallwood, C. A., Siemens, D. R., & Graham, C. H. (2014). A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Research, 74(3), 665-674. https://doi.org/10.1158/0008-5472.CAN-13-0992

Beesetti, S. L., Jayadev, M., Subhashini, G. V., Mansour, L., Alwasel, S., & Harrath, A. H. (2019). Andrographolide as a therapeutic agent against breast and ovarian cancers. Open life sciences, 14(1), 462-469. https://doi.org/10.1515/biol-2019-0052

BelAiba, R. S., Bonello, S., Zähringer, C., Schmidt, S., Hess, J., Kietzmann, T., & Görlach, A. (2007). Hypoxia up-regulates hypoxia-inducible factor-1α transcription by involving phosphatidylinositol 3-kinase and nuclear factor κB in pulmonary artery smooth muscle cells. Molecular biology of the cell, 18(12), 4691-4697. https://doi.org/10.1091/mbc.e07-04-0391

Bell, E. L., Klimova, T. A., Eisenbart, J., Moraes, C. T., Murphy, M. P., Budinger, G. S., & Chandel, N. S. (2007). The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. The Journal of cell biology, 177(6), 1029-1036. https://doi.org/10.1083/jcb.200609074

Bergers, G., & Hanahan, D. (2008). Modes of resistance to anti-angiogenic therapy. Nature Reviews Cancer, 8(8), 592-603. https://doi.org/10.1038/nrc2442

Bhowmik, A., Chakravarti, S., Ghosh, A., Shaw, R., Bhandary, S., Bhattacharyya, S., Sen, P. C., & Ghosh, M. K. (2017). Anti- SSTR2 peptide based targeted delivery of potent PLGA encapsulated 3, 3’-diindolylmethane nanoparticles through blood brain barrier prevents glioma progression. Oncotarget, 8(39), 65339-65358. https://doi.org/10.18632/oncotarget.18689

Boddy, J. L., Fox, S. B., Han, C., Campo, L., Turley, H., Kanga, S., Malone, P. R., & Harris, A. L. (2005). The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clinical cancer research, 11(21), 7658-7663. https://doi.org/10.1158/1078-0432.CCR-05-0460

Bokobza, S. M., Jiang, Y., Weber, A. M., Devery, A. M., & Ryan, A. J. (2014). Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells. Oncotarget, 5(13), 4765–4778. https://doi.org/10.18632/oncotarget.2017

Bos, R. (2004). Hypoxia-Inducible Factor-1α in carcinogenesis and progression of breast cancer. [Doctoral thesis]. Utrecht University.

Bos, R., Zhong, H., Hanrahan, C. F., Mommers, E. C., Semenza, G. L., Pinedo, H. M., Abeloff, M. D., Simons, J. W., Van Diest, P. J., & Van Der Wall, E. (2001). Levels of hypoxia-inducible factor-1α during breast carcinogenesis. Journal of the national cancer institute, 93(4), 309-314. https://doi.org/10.1093/jnci/93.4.309

Brizel, D. M., Scully, S. P., Harrelson, J. M., Layfield, L. J., Bean, J. M., Prosnitz, L. R., & Dewhirst, M. W. (1996). Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Research, 56(5), 941- 943.

Brugarolas, J., Obara, G., Beckermann, K. E., Rini, B., Lam, E. T., Hamilton, J., Schluep, T., Yi, M., Wong, S., & Mao, Z. L. (2024). A first-in-human phase 1 study of a tumor-directed RNA-interference drug against HIF2α in patients with advanced clear cell renal cell carcinoma. Clinical cancer research, 30(11), 2402-2411. https://doi.org/10.1158/1078-0432.CCR-23-3029

Bruick, R. K., & McKnight, S. L. (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 294(5545), 1337-1340. https://doi.org/ 10.1126/science.1066373

Callapina, M., Zhou, J., Schmid, T., Köhl, R., & Brüne, B. (2005). NO restores HIF-1α hydroxylation during hypoxia: role of reactive oxygen species. Free Radical Biology and Medicine, 39(7), 925-936. https://doi.org/10.1016/j.freeradbiomed.2005.05.009

Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., & Maxwell, P. (1998). Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 394(6692), 485-490. https://doi.org/10.1038/28867

Castelli, S., Ciccarone, F., Tavian, D., & Ciriolo, M. R. (2021). ROS-dependent HIF1α activation under forced lipid catabolism entails glycolysis and mitophagy as mediators of higher proliferation rate in cervical cancer cells. Journal of Experimental & Clinical Cancer Research, 40(1), 94. https://doi.org/10.1186/s13046-021-01887-w

Cavadas, M. A., Nguyen, L. K., & Cheong, A. (2013). Hypoxia-inducible factor (HIF) network: insights from mathematical models. Cell Communication and Signaling, 11(1), 42. https://doi.org/10.1186/1478-811X-11-42

Cavell, B. E., Syed Alwi, S. S., Donlevy, A. M., Proud, C. G., & Packham, G. (2012). Natural product-derived antitumor compound phenethyl isothiocyanate inhibits mTORC1 activity via TSC2. Journal of Natural Products, 75(6), 1051- 1057. https://doi.org/10.1021/np300049b

Chandel, N., Maltepe, E., Goldwasser, E., Mathieu, C., Simon, M., & Schumacker, P. (1998). Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proceedings of the National Academy of Sciences, 95(20), 11715-11720. https://doi.org/10.1073/pnas.95.20.11715

Chau, N.-M., Rogers, P., Aherne, W., Carroll, V., Collins, I., McDonald, E., Workman, P., & Ashcroft, M. (2005). Identification of novel small molecule inhibitors of hypoxia-inducible factor-1 that differentially block hypoxia-inducible factor-1 activity and hypoxia-inducible factor-1α induction in response to hypoxic stress and growth factors. Cancer Research, 65(11), 4918-4928. https://doi.org/10.1158/0008-5472.CAN-04-4453

Cheloni, G., Tanturli, M., Tusa, I., Ho DeSouza, N., Shan, Y., Gozzini, A., Mazurier, F., Rovida, E., Li, S., & Dello Sbarba, P. (2017). Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood, The Journal of the American Society of Hematology, 130(5), 655-665. https://doi.org/10.1182/blood-2016-10-745588

Chen, C., He, W., Huang, J., Wang, B., Li, H., Cai, Q., Su, F., Bi, J., Liu, H., & Zhang, B. (2018). LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment. Nature communications, 9(1), 3826. https://doi.org/10.1038/s41467-018-6152-x

Chen, L., Shi, Y., Yuan, J., Han, Y., Qin, R., Wu, Q., Jia, B., Wei, B., Wei, L., & Dai, G. (2014). HIF-1 alpha overexpression correlates with poor overall survival and disease-free survival in gastric cancer patients post-gastrectomy. PloS one, 9(3), e90678. https://doi.org/10.1371/journal.pone.0090678

Chen, S.-R., Dai, Y., Zhao, J., Lin, L., Wang, Y., & Wang, Y. (2018). A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii Hook F. Frontiers in pharmacology, 9, 331085. https://doi.org/10.3389/fphar.2018.00104

Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023). Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal transduction and targeted therapy, 8(1), 70. https://doi.org/10.1038/s41392-023-01332-8

Cheng, C.-W., Chen, P.-M., Hsieh, Y.-H., Weng, C.-C., Chang, C.-W., Yao, C.-C., Hu, L.-Y., Wu, P.-E., & Shen, C.-Y. (2015). Foxo3a-mediated overexpression of microRNA-622 suppresses tumor metastasis by repressing hypoxia-inducible factor-1α in ERK-responsive lung cancer. Oncotarget, 6(42), 44222. https://doi.org/10.18632/oncotarget.5826

Cheng, Z.-X., Sun, B., Wang, S.-J., Gao, Y., Zhang, Y.-M., Zhou, H.-X., Jia, G., Wang, Y.-W., Kong, R., & Pan, S.-H. (2011). Nuclear factor-κb–dependent epithelial to mesenchymal transition induced by HIF-1α activation in pancreatic cancer cells under hypoxic conditions. PloS one, 6(8), e23752. https://doi.org/10.1371/journal.pone.0023752

Chmelyuk, N., Kordyukova, M., Sorokina, M., Sinyavskiy, S., Meshcheryakova, V., Belousov, V., & Abakumova, T. (2025). Inhibition of Thioredoxin-Reductase by Auranofin as a Pro- Oxidant Anticancer Strategy for Glioblastoma: In Vitro and In Vivo Studies. International journal of molecular sciences, 26(5), 2084. https://doi.org/10.3390/ijms26052084

Cho, K. H., Yu, S.-L., Cho, D. Y., Park, C. G., & Lee, H. Y. (2015). Breast cancer metastasis suppressor 1 (BRMS1) attenuates TGF-β1-induced breast cancer cell aggressiveness through downregulating HIF-1α expression. BMC cancer, 15(1), 1-9. https://doi.org/10.1186/s12885-015-1864-y

Choi, J. Y., Jang, Y. S., Min, S. Y., & Song, J. Y. (2011). Overexpression of MMP-9 and HIF-1α in breast cancer cells under hypoxic conditions. Journal of breast cancer, 14(2), 88-95. https://doi.org/10.4048/jbc.2011.14.2.88

Coltella, N., Valsecchi, R., Ponente, M., Ponzoni, M., & Bernardi, R. (2015). Synergistic leukemia eradication by combined treatment with retinoic acid and HIF inhibition by EZN- 2208 (PEG-SN38) in preclinical models of PML-RARα and PLZF-RARα–driven leukemia. Clinical cancer research, 21(16), 3685-3694. https://doi.org/10.1158/1078-0432.CCR-14-3022

Comas, L., Polo, E., Domingo, M. P., Hernández, Y., Arias, M., Esteban, P., Martínez-Lostao, L., Pardo, J., Martínez de la Fuente, J., & Gálvez, E. M. (2019). Intracellular delivery of biologically-active fungal metabolite gliotoxin using magnetic nanoparticles. Materials, 12(7), 1092. https://doi.org/10.3390/ma12071092

Comerford, K. M., Wallace, T. J., Karhausen, J. r., Louis, N. A., Montalto, M. C., & Colgan, S. P. (2002). Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Research, 62(12), 3387-3394.

Correa, P. (2013). Gastric cancer: overview. Gastroenterology Clinics of North America, 42(2), 211-217. https://doi.org/10.1016/j.gtc.2013.01.002

Costa, M., Davidson, T. L., Chen, H., Ke, Q., Zhang, P., Yan, Y., Huang, C., & Kluz, T. (2005). Nickel carcinogenesis: epigenetics and hypoxia signaling. Mutation Research/ Fundamental and Molecular Mechanisms of Mutagenesis, 592(1-2), 79-88. https://doi.org/10.1016/j.mrfmmm.2005.06.008

Cowman, S., Pizer, B., & Sée, V. (2021). Downregulation of both mismatch repair and non-homologous end-joining pathways in hypoxic brain tumour cell lines. PeerJ, 9, e11275. https://doi.org/10.7717/peerj.11275

Cui, K., Liu, J., Huang, L., Qin, B., Yang, X., Li, L., Liu, Y., Gu, J., Wu, W., & Yu, Y. (2020). Andrographolide attenuates choroidal neovascularization by inhibiting the HIF-1α/ VEGF signaling pathway. Biochemical and biophysical research communications, 530(1), 60-66. https://doi.org/10.1016/j.bbrc.2020.06.130

Cui, X., Tinholt, M., Stavik, B., Dahm, A., Kanse, S., Jin, Y., Seidl, S., Sahlberg, K., Iversen, N., & Skretting, G. (2016). Effect of hypoxia on tissue factor pathway inhibitor expression in breast cancer. Journal of Thrombosis and Haemostasis, 14(2), 387-396. https://doi.org/10.1111/jth.13206

Dales, J. P., Beaufils, N., Silvy, M., Picard, C., Pauly, V., Pradel, V., Formisano-Tréziny, C., Bonnier, P., Giusiano, S., & Charpin, C. (2010). Hypoxia inducible factor 1α gene (HIF-1α) splice variants: potential prognostic biomarkers in breast cancer. BMC Medicine, 8(1), 1-11. https://doi.org/10.1186/1741-7015-8-44

Dales, J. P., Garcia, S., Meunier‐Carpentier, S., Andrac‐Meyer, L., Haddad, O., Lavaut, M. N., Allasia, C., Bonnier, P., & Charpin, C. (2005). Overexpression of hypoxia‐inducible factor HIF‐1α predicts early relapse in breast cancer: Retrospective study in a series of 745 patients. International journal of cancer, 116(5), 734-739. https://doi.org/10.1002/ijc.20984

Dames, S. A., Martinez-Yamout, M., De Guzman, R. N., Dyson, H. J., & Wright, P. E. (2002). Structural basis for Hif-1α/CBP recognition in the cellular hypoxic response. Proceedings of the National Academy of Sciences, 99(8), 5271-5276. https://doi.org/ 10.1073/pnas.082121399

Dat, N. T., Jin, X., Lee, J.-H., Lee, D., Hong, Y.-S., Lee, K., Kim, Y. H., & Lee, J. J. (2007). Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. Journal of Natural Products, 70(7), 1093-1097. https://doi.org/10.1021/np060482d

Dauer, P., Nomura, A., Saluja, A., & Banerjee, S. (2017). Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters. Pancreatology, 17(1), 7-12. https://doi.org/10.1016/j.pan.2016.12.010

Davis, L., Recktenwald, M., Hutt, E., Fuller, S., Briggs, M., Goel, A., & Daringer, N. (2022). Targeting HIF-2α in the tumor microenvironment: redefining the role of HIF-2α for solid cancer therapy. Cancers, 14(5), 1259. https://doi.org/10.3390/cancers14051259

Deep, G., Kumar, R., Nambiar, D. K., Jain, A. K., Ramteke, A. M., Serkova, N. J., Agarwal, C., & Agarwal, R. (2017). Silibinin inhibits hypoxia‐induced HIF‐1α‐mediated signaling, angiogenesis and lipogenesis in prostate cancer cells: in vitro evidence and in vivo functional imaging and metabolomics. Molecular carcinogenesis, 56(3), 833-848. https://doi.org/10.1002/mc.22537

Dengler, V. L., Galbraith, M. D., & Espinosa, J. M. (2014). Transcriptional regulation by hypoxia inducible factors. Critical reviews in biochemistry and molecular biology, 49(1), 1-15. https://doi.org/10.3109/10409238.2013.838205

Ding, X., Huang, R., Zhong, Y., Cui, N., Wang, Y., Weng, J., Chen, L., & Zang, M. (2020). CTHRC1 promotes gastric cancer metastasis via HIF-1α/CXCR4 signaling pathway. Biomedicine & Pharmacotherapy, 123, 109742. https://doi.org/10.1016/j.biopha.2019.109742

Dogra, R., & Vaishampayan, U. (2025). Hypoxia inducible factor-2α (HIF-2α) pathway inhibitors. Journal of Kidney Cancer and VHL, 12(3), 1-15. https://doi.org/10.15586/jkcvhl.v12i3.413

Donker, R. B., Mouillet, J.-F., Nelson, D. M., & Sadovsky, Y. (2007). The expression of Argonaute2 and related microRNA biogenesis proteins in normal and hypoxic trophoblasts. MHR: Basic science of reproductive medicine, 13(4), 273-279. https://doi.org/10.1093/molehr/gam006

Du, Z., Fujiyama, C., Chen, Y., & Masaki, Z. (2003). Expression of hypoxia-inducible factor 1α in human normal, benign, and malignant prostate tissue. Chinese medical journal, 116(12), 1936-1939.

Ellinghaus, P., Heisler, I., Unterschemmann, K., Haerter, M., Beck, H., Greschat, S., Ehrmann, A., Summer, H., Flamme, I., & Oehme, F. (2013). BAY 87‐2243, a highly potent and selective inhibitor of hypoxia‐induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer medicine, 2(5), 611-624. https://doi.org/10.1002/cam4.112

Elvidge, G., Glenny, L., Appelhoff, R., Ratcliffe, P., Ragoussis, J., & Gleadle, J. 404 Concordant regulation of gene expression by hypoxia and 2-oxoglutarate-dependent dioxygenase 405 inhibition: the role of HIF-1alpha, HIF-2alpha, and other pathways. J Biol Chem, 281(22), 15215-15406.

https://doi.org/10.1074/jbc.M511408200 Emerling, B. M., Platanias, L. C., Black, E., Nebreda, A. R., Davis, R. J., & Chandel, N. S. (2005). Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling. Molecular and cellular biology, 25(12), 4853-4862. https://doi.org/10.1128/MCB.25.12.4853-4862.2005

Epstein, A. C., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O’Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., & Dhanda, A. (2001). C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell, 107(1), 43-54. https://doi.org/10.1016/S0092-8674(01)00507-4

Erler, J. T., Bennewith, K. L., Nicolau, M., Dornhöfer, N., Kong, C., Le, Q.-T., Chi, J.-T. A., Jeffrey, S. S., & Giaccia, A. J. (2006). Lysyl oxidase is essential for hypoxia-induced metastasis. Nature, 440(7088), 1222-1226. https://doi.org/10.1038/nature04695

Ferreira, L. M. (2010). Cancer metabolism: the Warburg effect today. Experimental and molecular pathology, 89(3), 372- 380. https://doi.org/10.1016/j.yexmp.2010.08.006

Flügel, D., Görlach, A., Michiels, C., & Kietzmann, T. (2007). Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1 α and mediates its destabilization in a VHL-independent manner. Molecular and cellular biology, 27(9), 3253-3265. https://doi.org/10.1128/MCB.00015-07

Folkman, J. (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature medicine, 1(1), 27-30. https://doi.org/10.1038/nm0195-27

Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Molecular and cellular biology, 16(9), 4604-4613. https://doi.org/10.1128/MCB.16.9.4604

Franovic, A., Holterman, C. E., Payette, J., & Lee, S. (2009). Human cancers converge at the HIF-2α oncogenic axis. Proceedings of the National Academy of Sciences, 106(50), 21306-21311. https://doi.org/10.1073/pnas.0906432106

Fu, D., Yao, J.-J., Wang, H., Cui, W.-G., Leng, J., Ding, L.-Y., & Fan, K.-Y. (2019). Effects of EGCG on proliferation and apoptosis of gastric cancer SGC7901 cells viadown-regulation of HIF-1α and VEGFunder a hypoxic state. European Review for Medical & Pharmacological Sciences, 23(1), 155-161. https://doi.org/10.26355/eurrev_201901_16759

Fu, X. S., Choi, E., Bubley, G. J., & Balk, S. P. (2005). Identification of hypoxia‐inducible factor‐1α (HIF‐1α) polymorphism as a mutation in prostate cancer that prevents normoxia‐induced degradation. The Prostate, 63(3), 215-221. https://doi.org/10.1002/pros.20190

Galanis, A., Pappa, A., Giannakakis, A., Lanitis, E., Dangaj, D., & Sandaltzopoulos, R. (2008). Reactive oxygen species and HIF-1 signalling in cancer. Cancer Letters, 266(1), 12-20. https://doi.org/10.1016/j.canlet.2008.02.028

Gao, N., Ding, M., Zheng, J. Z., Zhang, Z., Leonard, S. S., Liu, K. J., Shi, X., & Jiang, B.-H. (2002). Vanadate-induced expression of hypoxia-inducible factor 1α and vascular endothelial growth factor through phosphatidylinositol 3-kinase/Akt pathway and reactive oxygen species. Journal of Biological Chemistry, 277(35), 31963-31971. https://doi.org/10.1074/jbc.M200082200

Gao, N., Jiang, B.-H., Leonard, S. S., Corum, L., Zhang, Z., Roberts, J. R., Antonini, J., Zheng, J. Z., Flynn, D. C., & Castranova, V. (2002). p38 Signaling-mediated hypoxia-inducible factor 1α and vascular endothelial growth factor induction by Cr (VI) in DU145 human prostate carcinoma cells. Journal of Biological Chemistry, 277(47), 45041-45048. https://doi.org/10.1074/jbc.M202775200

Gao, N., Shen, L., Zhang, Z., Leonard, S. S., He, H., Zhang, X.-G., Shi, X., & Jiang, B.-H. (2004). Arsenite induces HIF-1α and VEGF through PI3K, Akt and reactive oxygen species in DU145 human prostate carcinoma cells. Molecular and Cellular Biochemistry, 255(1), 33-45. https://doi.org/10.1023/B:MCBI.0000007259.65742.16

Ge, X., Liu, X., Lin, F., Li, P., Liu, K., Geng, R., Dai, C., Lin, Y., Tang, W., & Wu, Z. (2016). MicroRNA-421 regulated by HIF-1α promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget, 7(17), 24466-24482. https://doi.org/10.18632/oncotarget.8228

Gerald, D., Berra, E., Frapart, Y. M., Chan, D. A., Giaccia, A. J., Mansuy, D., Pouysségur, J., Yaniv, M., & Mechta-Grigoriou, F. (2004). JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell, 118(6), 781-794. https://doi.org/10.1016/j.cell.2004.08.025

Ghosh, R., Samanta, P., Sarkar, R., Biswas, S., Saha, P., Hajra, S., & Bhowmik, A. (2022). Targeting HIF-1α by natural and synthetic compounds: a promising approach for anti-cancer therapeutics development. Molecules, 27(16), 5192. https://doi.org/10.3390/molecules27165192

Giannakakis, A., Coukos, G., Hatzigeorgiou, A., Sandaltzopoulos, R., & Zhang, L. (2007). miRNA genetic alterations in human cancers. Expert opinion on biological therapy, 7(9), 1375- 1386. https://doi.org/10.1517/14712598.7.9.1375

Giatromanolaki, A., Koukourakis, M., Sivridis, E., Turley, H., Talks, K., Pezzella, F., Gatter, K., & Harris, A. (2001). Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. British Journal of Cancer, 85(6), 881-890. https://doi.org/10.1054/bjoc.2001.2018

Goda, N., Ryan, H. E., Khadivi, B., McNulty, W., Rickert, R. C., & Johnson, R. S. (2003). Hypoxia-inducible factor 1α is essential for cell cycle arrest during hypoxia. Molecular and cellular biology, 23(1), 359-369. https://doi.org/10.1128/MCB.23.1.359-369.2003

Goral, V. (2015). Pancreatic cancer: pathogenesis and diagnosis. Asian Pacific journal of cancer prevention, 16(14), 5619-5624. https://doi.org/10.7314/APJCP.2015.16.14.5619

Gordan, J. D., Thompson, C. B., & Simon, M. C. (2007). HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer cell, 12(2), 108-113. https://doi.org/10.1016/j.ccr.2007.07.006

Goyal, K., Goel, H., Baranwal, P., Dixit, A., Khan, F., Jha, N. K., Kesari, K. K., Pandey, P., Pandey, A., & Benjamin, M. (2022). Unravelling the molecular mechanism of mutagenic factors impacting human health. Environmental science and pollution research, 29(41), 61993-62013. https://doi.org/10.1007/s11356-021-15442-9

Greenberger, L. M., Horak, I. D., Filpula, D., Sapra, P., Westergaard, M., Frydenlund, H. F., Albæk, C., Schrøder, H., & Ørum, H. (2008). A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth. Molecular cancer therapeutics, 7(11), 3598-3608. https://doi.org/10.1158/1535-7163.MCT-08-0510

Greijer, A., & Van der Wall, E. (2004). The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. Journal of clinical pathology, 57(10), 1009-1014. https://doi.org/10.1136/jcp.2003.015032

Griffiths, E. A., Pritchard, S., Valentine, H. R., Whitchelo, N., Bishop, P., Ebert, M., Price, P. M., Welch, I., & West, C. M. (2007). Hypoxia-inducible factor-1α expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastro-oesophageal adenocarcinomas. British Journal of Cancer, 96(1), 95-103. https://doi.org/10.1038/sj.bjc.6603524

Gruber, G., Greiner, R. H., Hlushchuk, R., Aebersold, D. M., Altermatt, H. J., Berclaz, G., & Djonov, V. (2004). Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Research, 6(3), R191. https://doi.org/10.1186/bcr775

Gu, J., Yamamoto, H., Ogawa, M., Ngan, C. Y., Danno, K., Hemmi, H., Kyo, N., Takemasa, I., Ikeda, M., & Sekimoto, M. (2006). Hypoxia-induced up-regulation of angiopoietin-2 in colorectal cancer. Oncology reports, 15(4), 779-783. https://doi.org/10.3892/or.15.4.779

Gu, M., Singh, R. P., Dhanalakshmi, S., Agarwal, C., & Agarwal, R. (2007). Silibinin inhibits inflammatory and angiogenic attributes in photocarcinogenesis in SKH-1 hairless mice. Cancer Research, 67(7), 3483-3491. https://doi.org/10.1158/0008-5472.CAN-06-3955

Gutierrez, L. S., Suckow, M., Lawler, J., Ploplis, V. A., & Castellino, F. J. (2003). Thrombospondin 1—a regulator of adenoma growth and carcinoma progression in the APC Min/+ mouse model. Carcinogenesis, 24(2), 199-207. https://doi.org/10.1093/carcin/24.2.199

Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005). Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing. Cell metabolism, 1(6), 401-408. https://doi.org/10.1016/j.cmet.2005.05.001

Guzy, R. D., & Schumacker, P. T. (2006). Oxygen sensing by mitochondria at complex III: the paradox of increased reactive oxygen species during hypoxia. Experimental physiology, 91(5), 807-819. https://doi.org/10.1113/expphysiol.2006.033506

Haidar, Z., Fatema, K., Shoily, S. S., & Sajib, A. A. (2023). Disease-associated metabolic pathways affected by heavy metals and metalloid. Toxicology reports, 10, 554-570. https://doi.org/10.1016/j.toxrep.2023.04.010

Hajra, S., Basu, A., Singha Roy, S., Patra, A. R., & Bhattacharya, S. (2017). Attenuation of doxorubicin-induced cardiotoxicity and genotoxicity by an indole-based natural compound 3, 3′-diindolylmethane (DIM) through activation of Nrf2/ARE signaling pathways and inhibiting apoptosis. Free Radical Research, 51(9-10), 812-827. https://doi.org/10.1080/10715762.2017.1381694

Hallal, R., Nehme, R., Brachet‐Botineau, M., Nehme, A., Dakik, H., Deynoux, M., Dello Sbarba, P., Levern, Y., Zibara, K., & Gouilleux, F. (2020). Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells. Journal of cellular and molecular medicine, 24(17), 10052-10062. https://doi.org/10.1111/jcmm.15612

Han, S. Y., Kim, E.-S., You, B. H., Chae, H.-S., Lu, Q., Chin, Y.-W., Ahn, H.-C., Chung, S.-J., Lee, K., & Choi, Y. H. (2020). Effect of treatment period with LC478, a disubstituted adamantayl derivative, on P-glycoprotein inhibition: its application to increase docetaxel absorption in rats. Xenobiotica, 50(7), 863-874. https://doi.org/10.1080/00498254.2019.1700318

Hart, P. C., Kenny, H. A., Grassl, N., Watters, K. M., Litchfield, L. M., Coscia, F., Blaženović, I., Ploetzky, L., Fiehn, O., & Mann, M. (2019). Mesothelial cell HIF1α expression is metabolically downregulated by metformin to prevent oncogenic tumor-stromal crosstalk. Cell Reports, 29(12), 4086-4098. e4086. https://doi.org/10.1016/j.celrep.2019.11.079

He, G., Jiang, Y., Zhang, B., & Wu, G. (2014). The effect of HIF- 1alpha on glucose metabolism, growth and apoptosis of pancreatic cancerous cells. Asia Pacific journal of clinical nutrition, 23(1), 174-180. https://doi.org/10.6133/apjcn.2014.23.1.14

Hebert, C., Norris, K., Scheper, M. A., Nikitakis, N., & Sauk, J. J. (2007). High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Molecular cancer, 6(1), 5. https://doi.org/10.1186/1476-4598-6-5

Höckel, M., Schlenger, K., Mitze, M., Schäffer, U., & Vaupel, P. (1996). Hypoxia and radiation response in human tumors. Seminars in radiation oncology, 6(1), 3-9. https://doi.org/10.1016/S1053-4296(96)80031-2

Hoefflin, R., Harlander, S., Schäfer, S., Metzger, P., Kuo, F., Schönenberger, D., Adlesic, M., Peighambari, A., Seidel, P., & Chen, C.-y. (2020). HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nature communications, 11(1), 4111. https://doi.org/10.1038/s41467-020-17873-3

Hoffmann, C., Mao, X., Brown-Clay, J., Moreau, F., Al Absi, A., Wurzer, H., Sousa, B., Schmitt, F., Berchem, G., & Janji, B. (2018). Hypoxia promotes breast cancer cell invasion through HIF-1α-mediated up-regulation of the invadopodial actin bundling protein CSRP2. Scientific Reports, 8(1), 10191. https://doi.org/10.1038/s41598-018-28637-x

Hu, H., Miao, X.-K., Li, J.-Y., Zhang, X.-W., Xu, J.-J., Zhang, J.-Y., Zhou, T.-X., Hu, M.-N., Yang, W.-L., & Mou, L.-Y. (2020). YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1α and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells. European journal of pharmacology, 874, 172961. https://doi.org/10.1016/j.ejphar.2020.172961

Hu, N., Jiang, D., Huang, E., Liu, X., Li, R., Liang, X., Kim, S. H., Chen, X., Gao, J.-L., & Zhang, H. (2013). BMP9-regulated angiogenic signaling plays an important role in the osteogenic differentiation of mesenchymal progenitor cells. Journal of cell science, 126(2), 532-541. https://doi.org/10.1242/jcs.114231

Hua, Q., Mi, B., Xu, F., Wen, J., Zhao, L., Liu, J., & Huang, G. (2020). Hypoxia-induced lncRNA-AC020978 promotes proliferation and glycolytic metabolism of non-small cell lung cancer by regulating PKM2/HIF-1α axis. Theranostics, 10(11), 4762-4778. https://doi.org/10.7150/thno.43839

Huang, M., Du, H., Zhang, L., Che, H., & Liang, C. (2018). The association of HIF-1α expression with clinicopathological significance in prostate cancer: a meta-analysis. Cancer management and research, 10, 2809-2816. https://doi.org/10.2147/CMAR.S161762

Huang, X.-z., Wang, J., Huang, C., Chen, Y.-y., Shi, G.-y., Hu, Q.-s., & Yi, J. (2008). Emodin enhances cytotoxicity of chemotherapeutic drugs in prostate cancer cells: the mechanisms involve ROS-mediated suppression of multidrug resistance and hypoxia inducible factor-1. Cancer Biology & Therapy, 7(3), 468-475. https://doi.org/10.4161/cbt.7.3.5457

Hubmann, R., Sieghart, W., Schnabl, S., Araghi, M., Hilgarth, M., Reiter, M., Demirtas, D., Valent, P., Zielinski, C., & Jäger, U. (2017). Gliotoxin targets nuclear NOTCH2 in human solid tumor derived cell lines in vitro and inhibits melanoma growth in xenograft mouse model. Frontiers in pharmacology, 8, 319. https://doi.org/10.3389/fphar.2017.00319

Huss, W. J., Hanrahan, C. F., Barrios, R. J., Simons, J. W., & Greenberg, N. M. (2001). Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Research, 61(6), 2736-2743.

Ibrahim, N. O., Hahn, T., Franke, C., Stiehl, D. P., Wirthner, R., Wenger, R. H., & Katschinski, D. r. M. (2005). Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors. Cancer Research, 65(23), 11094- 11100. https://doi.org/10.1158/0008-5472.CAN-05-1877

Iommarini, L., Porcelli, A. M., Gasparre, G., & Kurelac, I. (2017). Non-canonical mechanisms regulating hypoxia-inducible factor 1 alpha in cancer. Frontiers in oncology, 7, 286. https://doi.org/10.3389/fonc.2017.00286

Islam, M. T. (2017). Andrographolide, a new hope in the prevention and treatment of metabolic syndrome. Frontiers in pharmacology, 8, 571. https://doi.org/10.3389/fphar.2017.00571

Isobe, T., Aoyagi, K., Koufuji, K., Shirouzu, K., Kawahara, A., Taira, T., & Kage, M. (2013). Clinicopathological significance of hypoxia-inducible factor-1 alpha (HIF-1α) expression in gastric cancer. International journal of clinical oncology, 18(2), 293-304. https://doi.org/10.1007/s10147-012-0378-8

James, F., Wootton, S., Jackson, A., Wiseman, M., Copson, E., & Cutress, R. (2015). Obesity in breast cancer–what is the risk factor? European journal of cancer, 51(6), 705-720. https://doi.org/10.1016/j.ejca.2015.01.057

Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., & Doroshow, J. H. (2014). Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors. Cancer chemotherapy and pharmacology, 73(2), 343-348. https://doi.org/10.1007/s00280-013-2362-z

Jia, Y., Guo, Y., Jin, Q., Qu, H., Qi, D., Song, P., Zhang, X., Wang, X., Xu, W., & Dong, Y. (2020). A SUMOylation-dependent HIF-1α/CLDN6 negative feedback mitigates hypoxia-induced breast cancer metastasis. Journal of Experimental & Clinical Cancer Research, 39(1), 42. https://doi.org/10.1186/s13046-020-01547-5

Jiang, B. H., Agani, F., Passaniti, A., & Semenza, G. L. (1997). V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Research, 57(23), 5328- 5335.

Jiang, B. H., Jiang, G., Zheng, J. Z., Lu, Z., Hunter, T., & Vogt, P. K. (2001). Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor. Cell Growth and Differentitaion, 12(7), 363-369.

Jiang, B. H., Zheng, J. Z., Aoki, M., & Vogt, P. K. (2000). Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proceedings of the National Academy of Sciences, 97(4), 1749-1753. https://doi.org/10.1073/pnas.040560897

Jiang, B., Siregar, U., Willeford, K. O., Luthe, D. S., & Williams, W. P. (1995). Association of a 33-kilodalton cysteine proteinase found in corn callus with the inhibition of fall armyworm larval growth. Plant Physiology, 108(4), 1631-1640. https://doi.org/10.1104/pp.108.4.1631

Jiang, C., Qian, Y., Bai, X., Li, S., Zhang, L., Xie, Y., Lu, Y., Lu, Z., Liu, B., & Jiang, B.-H. (2025). SLC7A5/E2F1/PTBP1/ PKM2 axis mediates progression and therapy effect of triple-negative breast cancer through the crosstalk of amino acid metabolism and glycolysis pathway. Cancer Letters, 617, 217612. https://doi.org/10.1016/j.canlet.2025.217612

Jiang, H., Guo, R., & Powell-Coffman, J. A. (2001). The Caenorhabditis elegans hif-1 gene encodes a bHLH-PAS protein that is required for adaptation to hypoxia. Proceedings of the National Academy of Sciences, 98(14), 7916-7921. https://doi.org/10.1073/pnas.141234698

Jiang, S., Zhang, M., Sun, J., & Yang, X. (2018). Casein kinase 1α: biological mechanisms and theranostic potential. Cell Communication and Signaling, 16(1), 23. https://doi.org/10.1186/s12964-018-0236-z

Jiang, Y., Wu, G.-H., He, G.-D., Zhuang, Q.-L., Xi, Q.-L., Zhang, B., Han, Y.-S., & Fang, J. (2015). The effect of silencing HIF-1α gene in BxPC-3 cell line on glycolysis-related gene expression, cell growth, invasion, and apoptosis. Nutrition and Cancer, 67(8), 1316-1325. https://doi.org/10.1080/01635581.2015.1085584

Jin, F., Zheng, X., Yang, Y., Yao, G., Ye, L., Doeppner, T. R., Hermann, D. M., Wang, H., & Dai, Y. (2019). Impairment of hypoxia-induced angiogenesis by LDL involves a HIF-centered signaling network linking inflammatory TNFα and angiogenic VEGF. Aging (Albany NY), 11(2), 328-349. https://doi.org/10.18632/aging.101726

Jing, Y., Liu, L. Z., Jiang, Y., Zhu, Y., Guo, N. L., Barnett, J., Rojanasakul, Y., Agani, F., & Jiang, B. H. (2012). Cadmium increases HIF-1 and VEGF expression through ROS, ERK, and AKT signaling pathways and induces malignant transformation of human bronchial epithelial cells. Toxicological sciences : an official journal of the Society of Toxicology, 125(1), 10–19. https://doi.org/10.1093/toxsci/kfr256

Jordan, B. F., Runquist, M., Raghunand, N., Gillies, R. J., Tate, W. R., Powis, G., & Baker, A. F. (2005). The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX- 12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clinical cancer research, 11(2), 529-536. https://doi.org/10.1158/1078-0432.529.11.2

Jun, H.-O., Kim, Y., Kwon, Y.-W., Hong, S.-S., Kim, K.-W., Shin, J., & Kim, T.-Y. (2007). Wondonin, a novel compound, inhibits hypoxia-induced angiogenesis through hypoxia-inducible factor 1 alpha. FEBS letters, 581(25), 4977-4982. https://doi.org/10.1016/j.febslet.2007.09.034

Jung, H.-J., Park, J.-W., Lee, J. S., Lee, S.-R., Jang, B.-C., Suh, S.-I., Suh, M.-H., & Baek, W.-K. (2009). Silibinin inhibits expression of HIF-1α through suppression of protein translation in prostate cancer cells. Biochemical and biophysical research communications, 390(1), 71-76. https://doi.org/10.1016/j.bbrc.2009.09.068

Jung, H. J., Kim, Y., Shin, J. Y., Sohng, J. K., & Kwon, H. J. (2015). Antiangiogenic activity of herboxidiene via downregulation of vascular endothelial growth factor receptor-2 and hypoxia-inducible factor-1α. Archives of pharmacal research, 38(9), 1728-1735. https://doi.org/10.1007/s12272-015-0625-4

Jung, J. H., Lee, H., Cao, B., Liao, P., Zeng, S. X., & Lu, H. (2020). RNA-binding motif protein 10 induces apoptosis and suppresses proliferation by activating p53. Oncogene, 39(5), 1031-1040. https://doi.org/10.1038/s41388-019-1034-9

Kaelin, W. G. (2005). ROS: really involved in oxygen sensing. Cell metabolism, 1(6), 357-358. https://doi.org/10.1016/j.cmet.2005.05.006

Kaelin, W. G., & Ratcliffe, P. J. (2008). Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Molecular cell, 30(4), 393-402. https://doi.org/10.1016/j.molcel.2008.04.009

Kamphues, C., Wittschieber, D., Klauschen, F., Kasajima, A., Dietel, M., Schmidt, S.-C., Glanemann, M., Bahra, M., Neuhaus, P., & Weichert, W. (2012). Prolyl hydroxylase domain 2 protein is a strong prognostic marker in human gastric cancer. Pathobiology, 79(1), 11-17. https://doi.org/10.1159/000330170

Kaur, B., Khwaja, F. W., Severson, E. A., Matheny, S. L., Brat, D. J., & Van Meir, E. G. (2005). Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncology, 7(2), 134-153. https://doi.org/10.1215/S1152851704001115

Kazi, A. A., Jones, J. M., & Koos, R. D. (2005). Chromatin immunoprecipitation analysis of gene expression in the rat uterus in vivo: estrogen-induced recruitment of both estrogen receptor α and hypoxia-inducible factor 1 to the vascular endothelial growth factor promoter. Molecular endocrinology, 19(8), 2006-2019. https://doi.org/10.1210/me.2004-0388

Keith, B., Johnson, R. S., & Simon, M. C. (2012). HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nature Reviews Cancer, 12(1), 9-22. https://doi.org/10.1038/nrc3183

Keith, B., & Simon, M. C. (2007). Hypoxia-inducible factors, stem cells, and cancer. Cell, 129(3), 465-472. https://doi.org/10.1016/j.cell.2007.04.019

Kessler, J., Hahnel, A., Wichmann, H., Rot, S., Kappler, M., Bache, M., & Vordermark, D. (2010). HIF-1α inhibition by siRNA or chetomin in human malignant glioma cells: effects on hypoxic radioresistance and monitoring via CA9 expression. BMC cancer, 10(1), 605. https://doi.org/10.1186/1471-2407-10-605

Khumukcham, S. S., Penugurti, V., Soni, A., Uppala, V., Hari, K., Jolly, M. K., Dwivedi, A., Pk, A. S., Padala, C., & Mukta, S. (2022). A reciprocal feedback loop between HIF-1α and HPIP controls phenotypic plasticity in breast cancer cells. Cancer Letters, 526, 12-28. https://doi.org/10.1016/j.canlet.2021.11.002

Kikuchi, H., Pino, M. S., Zeng, M., Shirasawa, S., & Chung, D. C. (2009). Oncogenic KRAS and BRAF differentially regulate hypoxia-inducible factor-1α and-2α in colon cancer. Cancer Research, 69(21), 8499-8506. https://doi.org/10.1158/0008-5472.CAN-09-2213

Kim, D. H., Sung, B., Kang, Y. J., Hwang, S. Y., Kim, M. J., Yoon, J.-H., Im, E., & Kim, N. D. (2015). Sulforaphane inhibits hypoxia-induced HIF-1α and VEGF expression and migration of human colon cancer cells. International journal of oncology, 47(6), 2226-2232. https://doi.org/10.3892/ijo.2015.3200

Kim, E. S., Kies, M. S., Fossella, F. V., Glisson, B. S., Zaknoen, S., Statkevich, P., Munden, R. F., Summey, C., Pisters, K. M., & Papadimitrakopoulou, V. (2005). Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane‐refractory/resistant nonsmall cell lung carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society, 104(3), 561-569. https://doi.org/10.1002/cncr.21188

Kim, J.-w., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006). HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell metabolism, 3(3), 177-185. https://doi.org/10.1016/j.cmet.2006.02.002

Kim, S. Y., San Ko, Y., Park, J., Choi, Y., Park, J.-W., Kim, Y., Pyo, J.-S., Yoo, Y. B., Lee, J.-S., & Lee, B. L. (2016). Forkhead transcription factor FOXO1 inhibits angiogenesis in gastric cancer in relation to SIRT1. Cancer research and treatment, 48(1), 345-354. https://doi.org/10.4143/crt.2014.247

Kim, W. Y., Oh, S. H., Woo, J.-K., Hong, W. K., & Lee, H.-Y. (2009). Targeting heat shock protein 90 overrides the resistance of lung cancer cells by blocking radiation-induced stabilization of hypoxia-inducible factor-1α. Cancer Research, 69(4), 1624-1632. https://doi.org/10.1158/0008-5472.CAN-08-0505

Kimbro, K., & Simons, J. (2006). Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocrine-related cancer, 13(3), 739-749. https://doi.org/10.1677/erc.1.00728

Kitajima, Y., & Miyazaki, K. (2013). The critical impact of HIF-1α on gastric cancer biology. Cancers, 5(1), 15-26. https://doi.org/10.3390/cancers5010015

Koh, M. Y., Lemos Jr, R., Liu, X., & Powis, G. (2011). The hypoxia-associated factor switches cells from HIF-1α-to HIF-2α- dependent signaling promoting stem cell characteristics, aggressive tumor growth and invasion. Cancer Research, 71(11), 4015-4027. https://doi.org/10.1158/0008-5472.CAN-10-4142

Koh, M. Y., & Powis, G. (2012). Passing the baton: the HIF switch. Trends in biochemical sciences, 37(9), 364-372. http://dx.doi. org/10.1016/j.tibs.2012.06.004

Koivunen, P., Lee, S., Duncan, C. G., Lopez, G., Lu, G., Ramkissoon, S., Losman, J. A., Joensuu, P., Bergmann, U., & Gross, S. (2012). Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature, 483(7390), 484-488. https://doi.org/10.1038/nature10898

Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005). Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Research, 65(19), 9047-9055. https://doi.org/10.1158/0008-5472.CAN-05-1235

Kong, X., Zhao, Y., Li, X., Tao, Z., Hou, M., & Ma, H. (2019). Overexpression of HIF-2alpha-dependent NEAT1 promotes the progression of non-small cell lung cancer through miR- 101-3p/SOX9/Wnt/beta-catenin signal pathway. Cellular Physiology and Biochemistry, 52(3), 368-381. https://doi.org/10.33594/000000026

Krock, B. L., Skuli, N., & Simon, M. C. (2011). Hypoxia-induced angiogenesis: good and evil. Genes & cancer, 2(12), 1117- 1133. https://doi.org/10.1177/1947601911423654

Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005). Silencing of microRNAs in vivo with ‘antagomirs’. Nature, 438(7068), 685-689. https://doi.org/10.1038/nature04303

Kubo, T., Maezawa, N., Osada, M., Katsumura, S., Funae, Y., & Imaoka, S. (2004). Bisphenol A, an environmental endocrine-disrupting chemical, inhibits hypoxic response via degradation of hypoxia-inducible factor 1α (HIF-1α): structural requirement of bisphenol A for degradation of HIF-1α. Biochemical and biophysical research communications, 318(4), 1006-1011. https://doi.org/10.1016/j.bbrc.2004.04.125

Kulshreshtha, R., Ferracin, M., Wojcik, S. E., Garzon, R., Alder, H., Agosto-Perez, F. J., Davuluri, R., Liu, C.-G., Croce, C. M., & Negrini, M. (2007). A microRNA signature of hypoxia. Molecular and cellular biology, 27(5), 1859-1867. https://doi.org/10.1128/MCB.01395-06

Kumar, S., Wang, G., Zheng, N., Cheng, W., Ouyang, K., Lin, H., Liao, Y., & Liu, J. (2019). HIMF (hypoxia-induced mitogenic factor)-IL (interleukin)-6 signaling mediates cardiomyocyte-fibroblast crosstalk to promote cardiac hypertrophy and fibrosis. Hypertension, 73(5), 1058-1070. https://doi.org/10.1161/HYPERTENSIONAHA.118.12267

Kurebayashi, J., Otsuki, T., Moriya, T., & Sonoo, H. (2001). Hypoxia reduces hormone responsiveness of human breast cancer cells. Japanese journal of cancer research, 92(10), 1093-1101. https://doi.org/10.1111/j.1349-7006.2001.tb01064.x

Lando, D., Peet, D. J., Gorman, J. J., Whelan, D. A., Whitelaw, M. L., & Bruick, R. K. (2002). FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes & development, 16(12), 1466-1471. https://doi.org/10.1101/gad.991402

Lautz, T. B., Jie, C., Clark, S., Naiditch, J. A., Jafari, N., Qiu, Y.-Y., Zheng, X., Chu, F., & Madonna, M. B. (2012). The effect of vorinostat on the development of resistance to doxorubicin in neuroblastoma. PloS one, 7(7), e40816. https://doi.org/10.1371/journal.pone.0040816

Lee, K., Kang, J. E., Park, S.-K., Jin, Y., Chung, K.-S., Kim, H.-M., Lee, K., Kang, M. R., Lee, M. K., & Song, K. B. (2010). LW6, a novel HIF-1 inhibitor, promotes proteasomal degradation of HIF-1α via upregulation of VHL in a colon cancer cell line. Biochemical pharmacology, 80(7), 982-989. https://doi.org/10.1016/j.bcp.2010.06.018

Lee, K., & Kim, H. M. (2011). A novel approach to cancer therapy using PX-478 as a HIF-1α inhibitor. Archives of pharmacal research, 34(10), 1583-1585. https://doi.org/10.1007/s12272-011-1021-3

Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009). RETRACTED: acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proceedings of the National Academy of Sciences, 106(42), 17910-17915. https://doi.org/10.1073/pnas.0909353106

Lee, M.-R., Lin, C., Lu, C.-C., Kuo, S.-C., Tsao, J.-W., Juan, Y.-N., Chiu, H.-Y., Lee, F.-Y., Yang, J.-S., & Tsai, F.-J. (2017). YC-1 induces G0/G1 phase arrest and mitochondria-dependent apoptosis in cisplatin-resistant human oral cancer CAR cells. Biomedicine, 7(2), 12. https://doi.org/10.1051/bmdcn/2017070205

Lee, P., Chandel, N. S., & Simon, M. C. (2020). Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nature reviews Molecular cell biology, 21(5), 268-283. https://doi.org/10.1038/s41580-020-0227-y

Lee, S., Bae, S., Kim, K., & Lee, Y. (2014). RUNX3 inhibits hypoxia-inducible factor-1α protein stability by interacting with prolyl hydroxylases in gastric cancer cells. Oncogene, 33(11), 1458-1467. https://doi.org/10.1038/onc.2013.76

Lee, S. H., Jee, J. G., Bae, J. S., Liu, K. H., & Lee, Y. M. (2015). A group of novel HIF‐1α inhibitors, glyceollins, blocks HIF‐1α synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding. Journal of Cellular Physiology, 230(4), 853-862. https://doi.org/10.1002/jcp.24813

Lee, Y.-M., Kim, G.-H., Park, E.-J., Oh, T.-I., Lee, S., Kan, S.-Y., Kang, H., Kim, B. M., Kim, J. H., & Lim, J.-H. (2019). Thymoquinone selectively kills hypoxic renal cancer cells by suppressing HIF-1α-mediated glycolysis. International journal of molecular sciences, 20(5), 1092. https://doi.org/10.3390/ijms20051092

Li, F., Aljahdali, I. A., Zhang, R., Nastiuk, K. L., Krolewski, J. J., & Ling, X. (2021). Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. Journal of Experimental & Clinical Cancer Research, 40(1), 254. https://doi.org/10.1186/s13046-021-02026-1

Li, J., Davidson, G., Huang, Y., Jiang, B.-H., Shi, X., Costa, M., & Huang, C. (2004). Nickel compounds act through phosphatidylinositol-3-kinase/Akt-dependent, p70S6k-independent pathway to induce hypoxia inducible factor transactivation and Cap43 expression in mouse epidermal Cl41 cells. Cancer Research, 64(1), 94-101. https://doi.org/10.1158/0008-5472.CAN-03-0737

Li, M.-H., Miao, Z.-H., Tan, W.-F., Yue, J.-M., Zhang, C., Lin, L.-P., Zhang, X.-W., & Ding, J. (2004). Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1α by promoting proteasome-mediated degradation. Clinical cancer research, 10(24), 8266-8274. https://doi.org/10.1158/1078-0432.CCR-04-0951

Li, X., Yue, Y., Zhou, Y., Fan, Y., Fan, C., Huang, Y., Wu, F., & Liu, Y. (2011). An oil-free microemulsion for intravenous delivery of diallyl trisulfide: Formulation and evaluation. International journal of pharmaceutics, 407(1-2), 158-166. https://doi.org/10.1016/j.ijpharm.2011.01.008

Li, Y., Zhang, Y., Li, X., Huang, Y., Chen, W., He, L., & Zhang, Y. (2021). Status of hypoxia-inducible factor-1α expression in non-small cell lung cancer. Die Pharmazie-An International Journal of Pharmaceutical Sciences, 76(9), 404-411. https://doi.org/10.1691/ph.2021.1524

Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., Shi, Q., Cao, Y., Lathia, J., & McLendon, R. E. (2009). Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer cell, 15(6), 501-513. https://doi.org/10.1016/j.ccr.2009.03.018

Liao, D., Corle, C., Seagroves, T. N., & Johnson, R. S. (2007). Hypoxia-inducible factor-1α is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Research, 67(2), 563-572. https://doi.org/10.1158/0008-5472.CAN-06-2701

Lin, S., Ma, R., Zheng, X.-Y., Yu, H., Liang, X., Lin, H., & Cai, X.-J. (2014). Meta-analysis of immunohistochemical expression of hypoxia inducible factor-1α as a prognostic role in gastric cancer. World journal of gastroenterology, 20(4), 1107-1113. https://doi.org/10.3748/wjg.v20.i4.1107

Liu, B., Han, Y., Jiang, L., Jiang, D., Li, W., Zhang, T., Zu, G., & Zhang, X. (2018). Clinicopathological and prognostic significance of the RUNX3 expression in gastric cancer: a systematic review and meta-analysis. International Journal of Surgery, 53, 122-128. https://doi.org/10.1016/j.ijsu.2018.03.041

Liu, L.-Z., Hu, X.-W., Xia, C., He, J., Zhou, Q., Shi, X., Fang, J., & Jiang, B.-H. (2006). Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1α expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radical Biology and Medicine, 41(10), 1521-1533. https://doi.org/10.1016/j.freeradbiomed.2006.08.003

Liu, L.-Z., Li, C., Chen, Q., Jing, Y., Carpenter, R., Jiang, Y., Kung, H.-F., Lai, L., & Jiang, B.-H. (2011). MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PloS one, 6(4), e19139. https://doi.org/10.1371/journal.pone.0019139

Liu, L., Zhao, X., Zou, H., Bai, R., Yang, K., & Tian, Z. (2016). Hypoxia promotes gastric cancer malignancy partly through the HIF-1α dependent transcriptional activation of the long non-coding RNA GAPLINC. Frontiers in Physiology, 7, 420. https://doi.org/10.3389/fphys.2016.00420

Liu, M., Du, K., Fu, Z., Zhang, S., & Wu, X. (2015). Hypoxia-inducible factor 1-alpha up-regulates the expression of phospholipase D2 in colon cancer cells under hypoxic conditions. Medical Oncology, 32(1), 394. https://doi.org/10.1007/s12032-014-0394-9

Liu, S., Zhang, K., Zhu, Q., Shen, Q., Zhang, Q., Yu, J., Chen, Y., & Lu, W. (2019). Synthesis and biological evaluation of paclitaxel and vorinostat co-prodrugs for overcoming drug resistance in cancer therapy in vitro. Bioorganic & Medicinal Chemistry, 27(7), 1405-1413. https://doi.org/10.1016/j.bmc.2019.02.046

Liu, X., Chen, Z., Xu, C., Leng, X., Cao, H., Ouyang, G., & Xiao, W. (2015). Repression of hypoxia-inducible factor α signaling by Set7-mediated methylation. Nucleic acids research, 43(10), 5081-5098. https://doi.org/10.1093/nar/gkv379

Lu, Y., Ji, N., Wei, W., Sun, W., Gong, X., & Wang, X. (2017). MiR- 142 modulates human pancreatic cancer proliferation and invasion by targeting hypoxia-inducible factor 1 (HIF-1α) in the tumor microenvironments. Biology open, 6(2), 252-259. https://doi.org/10.1242/bio.021774

Luo, D., Ren, H., Zhang, W., Xian, H., Lian, K., & Liu, H. (2019). Clinicopathological and prognostic value of hypoxia-inducible factor-1α in patients with bone tumor: a systematic review and meta-analysis. Journal of orthopaedic surgery and research, 14(1), 56. https://doi.org/10.1186/s13018-019-1101-5

Luo, F., Lu, F.-T., Cao, J.-X., Ma, W.-J., Xia, Z.-F., Zhan, J.-H., Zeng, K.-M., Huang, Y., Zhao, H.-Y., & Zhang, L. (2022). HIF-1α inhibition promotes the efficacy of immune checkpoint blockade in the treatment of non-small cell lung cancer. Cancer Letters, 531, 39-56. https://doi.org/10.1016/j.canlet.2022.01.027

Lv, H., Zhu, B., & Chen, D. (2024). The heterogeneity of tumor-associated macrophages and strategies to target it. Biocell, 48(3), 363. https://doi.org/10.32604/biocell.2023.046367

Ma, J., Zhang, L., Ru, G.-Q., Zhao, Z.-S., & Xu, W.-J. (2007). Upregulation of hypoxia inducible factor 1α mRNA is associated with elevated vascular endothelial growth factor expression and excessive angiogenesis and predicts a poor prognosis in gastric carcinoma. World journal of gastroenterology, 13(11), 1680-1686. https://doi.org/10.3748/wjg.v13.i11.1680

Ma, L., Li, G., Zhu, H., Dong, X., Zhao, D., Jiang, X., Li, J., Qiao, H., Ni, S., & Sun, X. (2014). 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and-2. Cancer Letters, 355(1), 96-105. https://doi.org/10.1016/j.canlet.2014.09.011

Ma, Y.-Y., Lin, H., Moh, J.-S., Chen, K.-D., Wang, I.-W., Ou, Y.-C., You, Y.-S., & Lung, C.-C. (2011). Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells. Taiwanese Journal of Obstetrics and Gynecology, 50(2), 165-171. https://doi.org/10.1016/j.tjog.2011.01.022

Ma, Z., Xiang, X., Li, S., Xie, P., Gong, Q., Goh, B.-C., & Wang, L. (2022). Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds. Seminars in cancer biology, 80, 379-390. https://doi.org/10.1016/j.semcancer.2020.09.011

Mabjeesh, N. J., Willard, M. T., Frederickson, C. E., Zhong, H., & Simons, J. W. (2003). Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clinical cancer research, 9(7), 2416-2425.

Magar, A. G., Morya, V. K., Kwak, M. K., Oh, J. U., & Noh, K. C. (2024). A molecular perspective on HIF-1α and angiogenic stimulator networks and their role in solid tumors: an update. International journal of molecular sciences, 25(6), 3313. https://doi.org/10.3390/ijms25063313

Maiso, P., Carvajal-Vergara, X., Ocio, E. M., López-Pérez, R., Mateo, G., Gutiérrez, N., Atadja, P., Pandiella, A., & San Miguel, J. F. (2006). The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Research, 66(11), 5781-5789. https://doi.org/10.1158/0008-5472.CAN-05-4186

Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010). Hypoxia-inducible factors and the response to hypoxic stress. Molecular cell, 40(2), 294-309. https://doi.org/10.1016/j.molcel.2010.09.022

Majumder, P. K., Febbo, P. G., Bikoff, R., Berger, R., Xue, Q., McMahon, L. M., Manola, J., Brugarolas, J., McDonnell, T. J., & Golub, T. R. (2004). mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature medicine, 10(6), 594-601. https://doi.org/10.1038/nm1052

Mangraviti, A., Raghavan, T., Volpin, F., Skuli, N., Gullotti, D., Zhou, J., Asnaghi, L., Sankey, E., Liu, A., & Wang, Y. (2017). HIF-1α-targeting acriflavine provides long term survival and radiological tumor response in brain cancer therapy. Scientific Reports, 7(1), 14978. https://doi.org/10.1038/s41598-017-14990-w

Marin-Valencia, I., Yang, C., Mashimo, T., Cho, S., Baek, H., Yang, X.-L., Rajagopalan, K. N., Maddie, M., Vemireddy, V., & Zhao, Z. (2012). Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. Cell metabolism, 15(6), 827-837. https://doi.org/10.1016/j.cmet.2012.05.001

Marton, I., Knežević, F., Ramić, S., Milošević, M., & Tomas, D. (2012). Immunohistochemical expression and prognostic significance of HIF-1α and VEGF-C in neuroendocrine breast cancer. Anticancer research, 32(12), 5227-5232.

Masoud, G. N., & Li, W. (2015). HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharmaceutica Sinica B, 5(5), 378-389. https://doi.org/10.1016/j.apsb.2015.05.007

Masson, N., Singleton, R. S., Trudgian, D. C., Ambrose, L. J., Miranda, M. X., Tian, Y.-M., Kessler, B. M., Schofield, C. J., & Ratcliffe, P. J. (2012). The FIH hydroxylase is a cellular peroxide sensor that modulates HIF transcriptional activity. EMBO reports, 13(3), 251-257. https://doi.org/10.1038/embor.2012.9

Maxwell, P., Dachs, G., Gleadle, J., Nicholls, L., Harris, A., Stratford, I., Hankinson, O., Pugh, C., and, & Ratcliffe, P. (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proceedings of the National Academy of Sciences, 94(15), 8104-8109. https://doi.org/10.1073/pnas.94.15.8104

Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001). Activation of the HIF pathway in cancer. Current opinion in genetics & development, 11(3), 293-299. https://doi.org/10.1016/S0959-437X(00)00193-3

Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999). The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature, 399(6733), 271-275. https://doi.org/10.1038/20459

Mazumdar, J., Hickey, M. M., Pant, D. K., Durham, A. C., Sweet- Cordero, A., Vachani, A., Jacks, T., Chodosh, L. A., Kissil, J. L., & Simon, M. C. (2010). HIF-2α deletion promotes Kras-driven lung tumor development. Proceedings of the National Academy of Sciences, 107(32), 14182-14187. https://doi.org/10.1073/pnas.1001296107

Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., & Naldini, L. (2011). Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer cell, 19(4), 512-526. https://doi.org/10.1016/j.ccr.2011.02.005

Metzen, E., Berchner-Pfannschmidt, U., Stengel, P., Marxsen, J. H., Stolze, I., Klinger, M., Huang, W. Q., Wotzlaw, C., Hellwig-Bürgel, T., & Jelkmann, W. (2003). Intracellular localisation of human HIF-1α hydroxylases: implications for oxygen sensing. Journal of cell science, 116(7), 1319-1326. https://doi.org/10.1242/jcs.00318

Metzen, E., Stiehl, D. P., Doege, K., Marxsen, J. H., Hellwig- Bürgel, T., & Jelkmann, W. (2005). Regulation of the prolyl hydroxylase domain protein 2 (phd2/egln-1) gene: identification of a functional hypoxia-responsive element. Biochemical Journal, 387(3), 711-717. https://doi.org/10.1042/BJ20041736

Minegishi, H., Fukashiro, S., Ban, H. S., & Nakamura, H. (2013). Discovery of indenopyrazoles as a new class of hypoxia inducible factor (HIF)-1 inhibitors. ACS Medicinal Chemistry Letters, 4(2), 297-301.2 https://doi.org/10.1021/ml3004632

Minervini, G., Pennuto, M., & Tosatto, S. C. (2020). The pVHL neglected functions, a tale of hypoxia-dependent and-independent regulations in cancer. Open Biology, 10(7), 200109. https://doi.org/10.1098/rsob.200109

Miranda, E., Nordgren, I. K., Male, A. L., Lawrence, C. E., Hoakwie, F., Cuda, F., Court, W., Fox, K. R., Townsend, P. A., & Packham, G. K. (2013). A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. Journal of the American Chemical Society, 135(28), 10418-10425. https://doi.org/10.1021/ja402993u

Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004). Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer cell, 5(5), 429-441. https://doi.org/10.1016/S1535-6108(04)00115-1

Monzon, F. A., Alvarez, K., Peterson, L., Truong, L., Amato, R. J., Hernandez-McClain, J., Tannir, N., Parwani, A. V., & Jonasch, E. (2011). Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Modern Pathology, 24(11), 1470-1479. https://doi.org/10.1038/modpathol.2011.107

Moreno-Manzano, V., Rodríguez-Jiménez, F. J., Acena-Bonilla, J. L., Fustero-Lardíes, S., Erceg, S., Dopazo, J., Montaner, D., Stojkovic, M., & Sánchez-Puelles, J. M. (2010). FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status. Journal of Biological Chemistry, 285(2), 1333-1342. https://doi.org/10.1074/jbc.M109.008326

Mottet, D., Dumont, V., Deccache, Y., Demazy, C., Ninane, N., Raes, M., & Michiels, C. (2003). Regulation of hypoxia-inducible factor-1α protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β pathway in HepG2 cells. Journal of Biological Chemistry, 278(33), 31277-31285. https://doi.org/10.1074/jbc.M300763200

Movafagh, S., Crook, S., & Vo, K. (2015). Regulation of hypoxia‐inducible factor‐1a by reactive oxygen species: new developments in an old debate. Journal of cellular biochemistry, 116(5), 696-703. https://doi.org/10.1002/jcb.25074

Musleh Ud Din, S., Streit, S. G., Huynh, B. T., Hana, C., Abraham, A.-N., & Hussein, A. (2024). Therapeutic targeting of hypoxia-inducible factors in cancer. International journal of molecular sciences, 25(4), 2060. https://doi.org/10.3390/ijms25042060

Muz, B., De La Puente, P., Azab, F., & Kareem Azab, A. (2015). The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia, 3, 83-92. https://doi.org/10.2147/HP.S93413

Mylonis, I., Chachami, G., Samiotaki, M., Panayotou, G., Paraskeva, E., Kalousi, A., Georgatsou, E., Bonanou, S., & Simos, G. (2006). Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1α. Journal of Biological Chemistry, 281(44), 33095-33106. https://doi.org/10.1074/jbc.M605058200

Nakazawa, M. S., Eisinger-Mathason, T. K., Sadri, N., Ochocki, J. D., Gade, T. P., Amin, R. K., & Simon, M. C. (2016). Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth. Nature communications, 7(1), 10539. https://doi.org/10.1038/ncomms10539

Namgung, Y., Kim, S. Y., & Kim, I. (2019). Down-regulation of Survivin by BIX-01294 pretreatment overcomes resistance of hepatocellular carcinoma cells to TRAIL. Anticancer research, 39(7), 3571-3578. https://doi.org/10.21873/anticanres.13503

Narita, T., Yin, S., Gelin, C. F., Moreno, C. S., Yepes, M., Nicolaou, K., & Van Meir, E. G. (2009). Identification of a novel small molecule HIF-1α translation inhibitor. Clinical cancer research, 15(19), 6128-6136. https://doi.org/10.1158/1078-0432.CCR-08-3180

Nasulewicz, A., Mazur, A., & Opolski, A. (2004). Role of copper in tumour angiogenesis—clinical implications. Journal of trace elements in Medicine and Biology, 18(1), 1-8. https://doi.org/10.1016/j.jtemb.2004.02.004

Nehme, R., Hallal, R., El Dor, M., Kobeissy, F., Gouilleux, F., Mazurier, F., & Zibara, K. (2021). Repurposing of acriflavine to target chronic myeloid leukemia treatment. Current medicinal chemistry, 28(11), 2218-2233. https://doi.org/10.2174/0929867327666200908114411

Nepal, M., Choi, H. J., Choi, B.-Y., Kim, S. L., Ryu, J.-H., Kim, D. H., Lee, Y.-H., & Soh, Y. (2012). Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypoxia-inducible factor-1α. European journal of pharmacology, 691(1-3), 28-37. https://doi.org/10.1016/j.ejphar.2012.06.028

Newman, B., Liu, Y., Lee, H.-F., Sun, D., & Wang, Y. (2012). HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells. Cancer Research, 72(17), 4551-4561. https://doi.org/10.1158/0008-5472.CAN-11-3600

Nguyen-Nielsen, M., & Borre, M. (2016). Diagnostic and therapeutic strategies for prostate cancer. Seminars in nuclear medicine, 46(6), 484-490. https://doi.org/10.1053/j.semnuclmed.2016.07.002

Ni, S.-Y., Wang, N., Luo, D.-Y., Hou, Y.-S., Li, Q.-Y., Chai, T., Zheng, Y.-D., Bu, X.-S., Zhu, E.-J., & Shi, X.-F. (2025). Discovery of novel salidroside derivatives as potent hypoxia inducible factor 1α (HIF-1α) signaling inhibitors to treat high altitude cerebral edema. European Journal of Medicinal Chemistry, 297, 117982. https://doi.org/10.1016/j.ejmech.2025.117982

Noman, M. Z., Hasmim, M., Messai, Y., Terry, S., Kieda, C., Janji, B., & Chouaib, S. (2015). Hypoxia: a key player in antitumor immune response. A review in the theme: cellular responses to hypoxia. American Journal of Physiology-Cell Physiology, 309(9), C569-C579. https://doi.org/10.1152/ajpcell.00207.2015

O’Neal, S. L., & Zheng, W. (2015). Manganese toxicity upon overexposure: a decade in review. Current environmental health reports, 2, 315-328. https://doi.org/10.1007/s40572-015-0056-x

Onnis, B., Rapisarda, A., & Melillo, G. (2009). Development of HIF‐1 inhibitors for cancer therapy. Journal of cellular and molecular medicine, 13(9a), 2780-2786. https://doi.org/10.1111/j.1582-4934.2009.00876.x

Ottaviani, G., & Jaffe, N. (2009). The epidemiology of osteosarcoma. Pediatric and adolescent osteosarcoma, 152, 3-13. https://doi.org/10.1007/978-1-4419-0284-9_1

Ou, X.-W., Wang, R.-X., Kang, M.-F., & Shi, J.-Q. (2018). Hypoxia promotes migration and invasion of gastric cancer cells by activating HIF-1α and inhibiting NDRG2 associated signaling pathway. European Review for Medical & Pharmacological Sciences, 22(23), 8237-8247. https://doi.org/10.26355/eurrev_201812_16518

Parangi, S., O’Reilly, M., Christofori, G., Holmgren, L., Grosfeld, J., Folkman, J., & Hanahan, D. (1996). Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proceedings of the National Academy of Sciences, 93(5), 2002- 2007. https://doi.org/10.1073/pnas.93.5.2002

Parhira, S., Zhu, G.-Y., Chen, M., Bai, L.-P., & Jiang, Z.-H. (2016). Cardenolides from Calotropis gigantea as potent inhibitors of hypoxia-inducible factor-1 transcriptional activity. Journal of Ethnopharmacology, 194, 930-936. https://doi.org/10.1016/j.jep.2016.10.070

Park, J.-H., Moon, M., Kim, J.-S., & Oh, S.-M. (2021). TOPK mediates hypoxia-induced epithelial-mesenchymal transition and the invasion of nonsmall-cell lung cancer cells via the HIF-1α/snail axis. Biochemical and biophysical research communications, 534, 941-949. https://doi.org/10.1016/j.bbrc.2020.10.068

Pechan, T., Jiang, B., Steckler, D., Ye, L., Lin, L., Luthe, D. S., & Williams, W. P. (1999). Characterization of three distinct cDNA clones encoding cysteine proteinases from maize (Zea mays L.) callus. Plant molecular biology, 40(1), 111-119. https://doi.org/10.1023/A:1026494813936

Peng, F., Du, Q., Peng, C., Wang, N., Tang, H., Xie, X., Shen, J., & Chen, J. (2015). A review: the pharmacology of isoliquiritigenin. Phytotherapy Research, 29(7), 969-977. https://doi.org/10.1002/ptr.5348

Petrella, B. L., Lohi, J., & Brinckerhoff, C. E. (2005). Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2α in von Hippel–Lindau renal cell carcinoma. Oncogene, 24(6), 1043-1052. https://doi.org/10.1038/sj.onc.1208305

Poon, E., Harris, A. L., & Ashcroft, M. (2009). Targeting the hypoxia-inducible factor (HIF) pathway in cancer. Expert reviews in molecular medicine, 11, e26. https://doi.org/10.1017/S1462399409001173

Pua, L. J. W., Mai, C.-W., Chung, F. F.-L., Khoo, A. S.-B., Leong, C.-O., Lim, W.-M., & Hii, L.-W. (2022). Functional roles of JNK and p38 MAPK signaling in nasopharyngeal carcinoma. International journal of molecular sciences, 23(3), 1108. https://doi.org/10.3390/ijms23031108

Qannita, R. A., Alalami, A. I., Harb, A. A., Aleidi, S. M., Taneera, J., Abu-Gharbieh, E., El-Huneidi, W., Saleh, M. A., Alzoubi, K. H., & Semreen, M. H. (2024). Targeting hypoxia-inducible factor-1 (HIF-1) in cancer: emerging therapeutic strategies and pathway regulation. Pharmaceuticals, 17(2), 195. https://doi.org/10.3390/ph17020195

Qian, Y., Jiang, B., Flynn, D. C., Leonard, S. S., Wang, S., Zhang, Z., Ye, J., Chen, F., Wang, L., & Shi, X. (2001). Cr (VI) increases tyrosine phosphorylation through reactive oxygen species-mediated reactions. Molecular and Cellular Biochemistry, 222(1-2), 199-204. https://doi.org/10.1023/A:1017926531890

Qin, X., Jiang, B., & Zhang, Y. (2016). 4E-BP1, a multifactor regulated multifunctional protein. Cell cycle, 15(6), 781-786. https://doi.org/10.1080/15384101.2016.1151581

Rahman, M. A., Jalouli, M., Bhajan, S. K., Al-Zharani, M., & Harrath, A. H. (2025). The Role of Hypoxia-Inducible Factor-1α (HIF-1α) in the Progression of Ovarian Cancer: Perspectives on Female Infertility. Cells, 14(6), 437. https://doi.org/10.3390/cells14060437

Raninga, P. V., Di Trapani, G., Vuckovic, S., Bhatia, M., & Tonissen, K. F. (2015). Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma. Oncotarget, 6(17), 15410-15424. https://doi.org/10.18632/oncotarget.3795

Rankin, E. B., & Giaccia, A. J. (2016). Hypoxic control of metastasis. Science, 352(6282), 175-180. https://doi.org/10.1126/science.aaf4405

Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004). Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications. Cancer Research, 64(4), 1475-1482. https://doi.org/10.1158/0008-5472.CAN-03-3139

Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000). Regulation of tumor angiogenesis by p53- induced degradation of hypoxia-inducible factor 1α. Genes & development, 14(1), 34-44. https://doi.org/10.1101/gad.14.1.34

Ravizza, R., Molteni, R., Gariboldi, M. B., Marras, E., Perletti, G., & Monti, E. (2009). Effect of HIF-1 modulation on the response of two-and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. European journal of cancer, 45(5), 890-898. https://doi.org/10.1016/j.ejca.2008.12.021

Rawla, P. (2019). Epidemiology of prostate cancer. World journal of oncology, 10(2), 63-89. https://doi.org/10.14740/wjon1191

Reece, K. M., Richardson, E. D., Cook, K. M., Campbell, T. J., Pisle, S. T., Holly, A. J., Venzon, D. J., Liewehr, D. J., Chau, C. H., & Price, D. K. (2014). Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer. Molecular cancer, 13(1), 91. https://doi.org/10.1186/1476-4598-13-91

Ren, H.-Y., Zhang, Y.-H., Li, H.-Y., Xie, T., Sun, L.-L., Zhu, T., Wang, S.-D., & Ye, Z.-M. (2016). Prognostic role of hypoxia-inducible factor-1 alpha expression in osteosarcoma: a meta-analysis. OncoTargets and therapy, 9, 1477-1487. https://doi.org/10.2147/OTT.S95490

Riby, J. E., Firestone, G. L., & Bjeldanes, L. F. (2008). 3, 3′-Diindolylmethane reduces levels of HIF-1α and HIF-1 activity in hypoxic cultured human cancer cells. Biochemical pharmacology, 75(9), 1858-1867. https://doi.org/10.1016/j.bcp.2008.01.017

Richard, D. E., Berra, E., & Pouysségur, J. (2000). Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1α in vascular smooth muscle cells. Journal of Biological Chemistry, 275(35), 26765-26771. https://doi.org/10.1016/S0021-9258(19)61441-9

Robey, I. F., Lien, A. D., Welsh, S. J., Baggett, B. K., & Gillies, R. J. (2005). Hypoxia-inducible factor-1α and the glycolytic phenotype in tumors. Neoplasia, 7(4), 324-330. https://doi.org/10.1593/neo.04430

Roy, S., Kaur, M., Agarwal, C., Tecklenburg, M., Sclafani, R. A., & Agarwal, R. (2007). p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Molecular cancer therapeutics, 6(10), 2696-2707. https://doi.org/10.1158/1535-7163.MCT-07-0104

Rugamba, A., Kang, D. Y., Sp, N., Jo, E. S., Lee, J.-M., Bae, S. W., & Jang, K.-J. (2021). Silibinin regulates tumor progression and tumorsphere formation by suppressing PD-L1 expression in non-small cell lung cancer (NSCLC) cells. Cells, 10(7), 1632. https://doi.org/10.3390/cells10071632

Salnikow, K., An, W. G., Melillo, G., Blagosklonny, M. V., & Costa, M. (1999). Nickel-induced transformation shifts the balance between HIF-1 and p53 transcription factors. Carcinogenesis, 20(9), 1819-1823. https://doi.org/10.1093/carcin/20.9.1819

Sang, N., Stiehl, D. P., Bohensky, J., Leshchinsky, I., Srinivas, V., & Caro, J. (2003). MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300. Journal of Biological Chemistry, 278(16), 14013-14019. https://doi.org/10.1074/jbc.M209702200

Santos, A. I., Carreira, B. P., Nobre, R. J., Carvalho, C. M., & Araújo, I. M. (2014). Stimulation of neural stem cell proliferation by inhibition of phosphodiesterase 5. Stem Cells International, 2014(1), 878397. https://doi.org/10.1155/2014/878397

Saramäki, O. R., Savinainen, K. J., Nupponen, N. N., Bratt, O., & Visakorpi, T. (2001). Amplification of hypoxia-inducible factor 1α gene in prostate cancer. Cancer Genetics and Cytogenetics, 128(1), 31-34. https://doi.org/10.1016/S0165-4608(01)00396-X

Sarighieh, M. A., Montazeri, V., Shadboorestan, A., Ghahremani, M. H., & Ostad, S. N. (2020). The inhibitory effect of curcumin on hypoxia inducer factors (Hifs) as a regulatory factor in the growth of tumor cells in breast cancer stem-like cells. Drug Research, 70(11), 512-518. https://doi.org/10.1055/a-1201-2602

Sarkar, N., Das, B., Bishayee, A., & Sinha, D. (2020). Arsenal of phytochemicals to combat against arsenic-induced mitochondrial stress and cancer. Antioxidants & Redox Signaling, 33(17), 1230-1256. https://doi.org/10.1089/ars.2019.7950

Sazakli, E. (2024). Human health effects of oral exposure to chromium: A systematic review of the epidemiological evidence. International Journal of Environmental Research and Public Health, 21(4), 406. https://doi.org/10.3390/ijerph21040406

Scheuermann, T. H., Li, Q., Ma, H.-W., Key, J., Zhang, L., Chen, R., Garcia, J. A., Naidoo, J., Longgood, J., & Frantz, D. E. (2013). Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nature chemical biology, 9(4), 271- 276. https://doi.org/10.1038/nchembio.1185

Scheuermann, T. H., Tomchick, D. R., Machius, M., Guo, Y., Bruick, R. K., & Gardner, K. H. (2009). Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor. Proceedings of the National Academy of Sciences, 106(2), 450-455. https://doi.org/10.1073/pnas.0808092106

Schwartz, D. L., Bankson, J. A., Lemos Jr, R., Lai, S. Y., Thittai, A. K., He, Y., Hostetter, G., Demeure, M. J., Von Hoff, D. D., & Powis, G. (2010). Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer. Molecular cancer therapeutics, 9(7), 2057-2067. https://doi.org/10.1158/1535-7163.MCT-09-0768

Semenza, G. L. (2002). HIF-1 and tumor progression: pathophysiology and therapeutics. Trends in molecular medicine, 8(4), S62-S67. https://doi.org/10.1016/S1471-4914(02)02317-1

Semenza, G. L. (2010). HIF-1: upstream and downstream of cancer metabolism. Current opinion in genetics & development, 20(1), 51-56. https://doi.org/10.1016/j.gde.2009.10.009

Semenza, G. L. (2013). HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. The Journal of clinical investigation, 123(9), 3664-3671. https://doi.org/10.1172/JCI67230

Semenza, G. L. (2025). Development of small molecule inhibitors of hypoxia-inducible factors for cancer therapy. Pharmacological reviews, 77(5), 100075. https://doi.org/10.1016/j.pharmr.2025.100075

Semenza, G. L., Dureza, R. C., Traystman, M. D., Gearhart, J. D., & Antonarakis, S. E. (1990). Human erythropoietin gene expression in transgenic mice: multiple transcription initiation sites and cis-acting regulatory elements. Molecular and cellular biology, 10(3), 930-938. https://doi.org/10.1128/mcb.10.3.930-938.1990

Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991). Hypoxia-inducible nuclear factors bind to an enhancer element located 3’to the human erythropoietin gene. Proceedings of the National Academy of Sciences, 88(13), 5680-5684. https://doi.org/10.1073/pnas.88.13.5680

Semenza, G. L., & Wang, G. L. (1992). A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Molecular and cellular biology, 12(12), 5447-5454. https://doi.org/10.1128/mcb.12.12.5447-5454.1992

Sennino, B., & McDonald, D. M. (2012). Controlling escape from angiogenesis inhibitors. Nature Reviews Cancer, 12(10), 699- 709. https://doi.org/10.1038/nrc3366

Shaikat, A. H., Azad, S. A. K., Tamim, M. A. R., Ullah, M. S., Amin, M. N., Sabbir, M. K., Tarun, M. T. I., Mostaq, M. S., Sabrin, S., & Mahmud, M. Z. (2026). Investigating hypoxia-inducible factor signaling in cancer: mechanisms, clinical implications, targeted therapeutic strategies, and resistance. Cancer Pathogenesis and Therapy, 4(03), 174-191. https://doi.org/10.1016/j.cpt.2025.07.003

Shamis, S. A., McMillan, D. C., & Edwards, J. (2021). The relationship between hypoxia-inducible factor 1α (HIF-1α) and patient survival in breast cancer: Systematic review and meta-analysis. Critical reviews in oncology/hematology, 159, 103231. https://doi.org/10.1016/j.critrevonc.2021.103231

Sharbeen, G., McCarroll, J. A., Akerman, A., Kopecky, C., Youkhana, J., Kokkinos, J., Holst, J., Boyer, C., Erkan, M., & Goldstein, D. (2021). Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition. Cancer Research, 81(13), 3461-3479. https://doi.org/10.1158/0008-5472.CAN-20-2496

Sharfalddin, A. A., Al-Younis, I. M., Mohammed, H. A., Dhahri, M., Mouffouk, F., Abu Ali, H., Anwar, M. J., Qureshi, K. A., Hussien, M. A., & Alghrably, M. (2022). Therapeutic properties of vanadium complexes. Inorganics, 10(12), 244. https://doi.org/10.3390/inorganics10120244

Shaw, R. J., & Cantley, L. C. (2006). Ras, PI (3) K and mTOR signalling controls tumour cell growth. Nature, 441(7092), 424-430. https://doi.org/10.1038/nature04869

Shen, L., Chen, Y.-L., Huang, C.-C., Shyu, Y.-C., Seftor, R. E., Seftor, E. A., Hendrix, M. J., Chien, D.-S., & Chu, Y.-W. (2023). CVM-1118 (foslinanib), a 2-phenyl-4-quinolone derivative, promotes apoptosis and inhibits vasculogenic mimicry via targeting TRAP1. Pathology and Oncology Research, 29, 1611038. https://doi.org/10.3389/pore.2023.1611038

Shevrin, D. H., Lad, T. E., Guinan, P., Kilton, L. J., Greenburg, A., Johnson, P., Blough, R. R., & Hoyer, H. (1994). Phase II trial of echinomycin in advanced hormone-resistant prostate cancer: an Illinois cancer council study. Investigational new drugs, 12(1), 65-66. https://doi.org/10.1007/BF00873239

Singh, R. P., & Agarwal, R. (2006). Prostate cancer chemoprevention by silibinin: bench to bedside. Molecular Carcinogenesis, 45(6), 436-442. https://doi.org/10.1002/mc.20223

Singh, R. P., Deep, G., Chittezhath, M., Kaur, M., Dwyer-Nield, L. D., Malkinson, A. M., & Agarwal, R. (2006). Effect of silibinin on the growth and progression of primary lung tumors in mice. Journal of the national cancer institute, 98(12), 846-855. https://doi.org/10.1093/jnci/djj231

Skinner, H. D., Zheng, J. Z., Fang, J., Agani, F., & Jiang, B.-H. (2004). Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1α, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. Journal of Biological Chemistry, 279(44), 45643-45651. https://doi.org/10.1074/jbc.M404097200

Skuli, N., Liu, L., Runge, A., Wang, T., Yuan, L., Patel, S., Iruela- Arispe, L., Simon, M. C., & Keith, B. (2009). Endothelial deletion of hypoxia-inducible factor–2α (HIF-2α) alters vascular function and tumor angiogenesis. Blood, The Journal of the American Society of Hematology, 114(2), 469- 477. https://doi.org/10.1182/blood-2008-12-193581

Smalley, K. S., & Eisen, T. G. (2003). Farnesyl transferase inhibitor SCH66336 is cytostatic, pro‐apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. International journal of cancer, 105(2), 165-175. https://doi.org/10.1002/ijc.11064

Sofer, A., Lei, K., Johannessen, C. M., & Ellisen, L. W. (2005). Regulation of mTOR and cell growth in response to energy stress by REDD1. Molecular and cellular biology, 25(14), 5834-5845. https://doi.org/10.1128/MCB.25.14.5834-5845.2005

Song, J. G., Lee, Y. S., Park, J.-A., Lee, E.-H., Lim, S.-J., Yang, S. J., Zhao, M., Lee, K., & Han, H.-K. (2016). Discovery of LW6 as a new potent inhibitor of breast cancer resistance protein. Cancer chemotherapy and pharmacology, 78(4), 735-744. https://doi.org/10.1007/s00280-016-3127-2

Song, M. S., Salmena, L., & Pandolfi, P. P. (2012). The functions and regulation of the PTEN tumour suppressor. Nature reviews Molecular cell biology, 13(5), 283-296. https://doi.org/10.1038/nrm3330

Stiehl, D. P., Jelkmann, W., Wenger, R. H., & Hellwig-Bürgel, T. (2002). Normoxic induction of the hypoxia-inducible factor 1α by insulin and interleukin-1β involves the phosphatidylinositol 3-kinase pathway. FEBS letters, 512(1- 3), 157-162. https://doi.org/10.1016/S0014-5793(02)02247-0

Ströfer, M., Jelkmann, W., & Depping, R. (2011). Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells: the role of HIF. Strahlentherapie und Onkologie, 187(7), 393-400. https://doi.org/10.1007/s00066-011-2248-0

Strowitzki, M. J., Cummins, E. P., & Taylor, C. T. (2019). Protein hydroxylation by hypoxia-inducible factor (HIF) hydroxylases: unique or ubiquitous? Cells, 8(5), 384. https://doi.org/10.3390/cells8050384

Sullivan, R., & Graham, C. H. (2007). Hypoxia-driven selection of the metastatic phenotype. Cancer and Metastasis Reviews, 26(2), 319-331. https://doi.org/10.1007/s10555-007-9062-2

Sun, G., Wang, Y., & Hu, W. (2014). Correlation between HIF-1α expression and breast cancer risk: a meta-analysis. Breast Journal, 20(2), 213-215. doi. 10.1111/tbj.12238

Sun, S., Ma, J., Xie, P., Wu, Z., & Tian, X. (2020). Hypoxia‐responsive miR‐141–3p is involved in the progression of breast cancer via mediating the HMGB1/HIF‐1α signaling pathway. The journal of gene medicine, 22(10), e3230. https://doi.org/10.1002/jgm.3230

Swinson, D. E., Jones, J. L., Richardson, D., Wykoff, C., Turley, H., Pastorek, J., Taub, N., Harris, A. L., & O’Byrne, K. J. (2003). Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non–small-cell lung cancer. Journal of Clinical Oncology, 21(3), 473-482. https://doi.org/10.1200/JCO.2003.11.132

Taguchi, A., Yanagisawa, K., Tanaka, M., Cao, K., Matsuyama, Y., Goto, H., & Takahashi, T. (2008). Identification of hypoxia-inducible factor-1α as a novel target for miR-17-92 microRNA cluster. Cancer Research, 68(14), 5540-5545. https://doi.org/10.1158/0008-5472.CAN-07-6460

Takasaki, C., Kobayashi, M., Ishibashi, H., Akashi, T., & Okubo, K. (2016). Expression of hypoxia-inducible factor-1α affects tumor proliferation and antiapoptosis in surgically resected lung cancer. Molecular and clinical oncology, 5(2), 295-300. https://doi.org/10.3892/mco.2016.937

Tal, R., Shaish, A., Bangio, L., Peled, M., Breitbart, E., & Harats, D. (2008). Activation of C-transactivation domain is essential for optimal HIF-1α-mediated transcriptional and angiogenic effects. Microvascular research, 76(1), 1-6. https://doi.org/10.1016/j.mvr.2008.03.002

Tang, N., Wang, L., Esko, J., Giordano, F. J., Huang, Y., Gerber, H.-P., Ferrara, N., & Johnson, R. S. (2004). Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer cell, 6(5), 485-495. https://doi.org/10.1016/j.ccr.2004.09.026

Thurston, G., Suri, C., Smith, K., McClain, J., Sato, T., Yancopoulos, G., & McDonald, D. (1999). Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science, 286(5449), 2511-2514. https://doi.org/10.1126/science.286.5449.2511

Tian, Y., Bai, F., & Zhang, D. (2022). HIF1α: A Novel Biomarker with Potential Prognostic and Immunotherapy in Pan‐cancer. Oxidative Medicine and Cellular Longevity, 2022(1), 1246267. https://doi.org/10.1155/2022/1246267

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: a cancer journal for clinicians, 65(2), 87-108. https://doi.org/10.3322/caac.21262

Ullah, A., Leong, S. W., Wang, J., Wu, Q., Ghauri, M. A., Sarwar, A., Su, Q., & Zhang, Y. (2021). Cephalomannine inhibits hypoxia-induced cellular function via the suppression of APEX1/HIF-1α interaction in lung cancer. Cell Death & Disease, 12(5), 490. https://doi.org/10.1038/s41419-021-03771-z

Ullah, A., Ullah, N., Nawaz, T., & Aziz, T. (2023). Molecular mechanisms of sanguinarine in cancer prevention and treatment. Anti-Cancer Agents in Medicinal Chemistry, 23(7), 765-778. https://doi.org/10.2174/1871520622666220831124321

Van Dyke, M. M., & Dervan, P. B. (1984). Echinomycin binding sites on DNA. Science, 225(4667), 1122-1127. https://doi.org/10.1126/science.6089341

Vaupel, P. (2004). The role of hypoxia-induced factors in tumor progression. The Oncologist, 9(S5), 10-17. https://doi.org/10.1634/theoncologist.9-90005-10

Vlaminck, B., Toffoli, S., Ghislain, B., Demazy, C., Raes, M., & Michiels, C. (2007). Dual effect of echinomycin on hypoxia‐inducible factor‐1 activity under normoxic and hypoxic conditions. The FEBS journal, 274(21), 5533-5542. https://doi.org/10.1111/j.1742-4658.2007.06072.x

Vleugel, M., Greijer, A., Shvarts, A., Van Der Groep, P., Van Berkel, M., Aarbodem, Y., Van Tinteren, H., Harris, A., Van Diest, P., & Van Der Wall, E. (2005). Differential prognostic impact of hypoxia induced and diffuse HIF-1α expression in invasive breast cancer. Journal of clinical pathology, 58(2), 172-177. https://doi.org/10.1136/jcp.2004.019885

Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., & Ferracin, M. (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences, 103(7), 2257-2261. https://doi.org/10.1073/pnas.0510565103

Wang, C., Han, C., Zhang, Y., & Liu, F. (2018). LncRNA PVT1 regulate expression of HIF1α via functioning as ceRNA for miR-199a-5p in non-small cell lung cancer under hypoxia. Molecular medicine reports, 17(1), 1105-1110. https://doi.org/10.3892/mmr.2017.7962

Wang, E.-j., & Johnson, W. W. (2003). The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2. Chemotherapy, 49(6), 303-308. https://doi.org/10.1159/000074531

Wang, G. L., Jiang, B.-h., Rue, E. A., & Semenza, G. L. (1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences, 92(12), 5510-5514. https://doi.org/10.1073/pnas.92.12.5510

Wang, G. L., & Semenza, G. L. (1993). Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood, 82(12), 3610-3615. https://doi.org/10.1182/blood.V82.12.3610.3610

Wang, G. L., & Semenza, G. L. (1995). Purification and characterization of hypoxia-inducible factor 1. Journal of Biological Chemistry, 270(3), 1230-1237. https://doi.org/10.1074/jbc.270.3.1230

Wang, H., Qin, C., Han, F., Wang, X., & Li, N. (2014). HIF-2alpha as a prognostic marker for breast cancer progression and patient survival. Genet Mol Res, 13(2), 2817-2826. http:// dx.doi.org/10.4238/2014.January.22.6

Wang, H., Wang, L., Pan, H., Wang, Y., Shi, M., Yu, H., Wang, C., Pan, X., & Chen, Z. (2021). Exosomes derived from macrophages enhance aerobic glycolysis and chemoresistance in lung cancer by stabilizing c-Myc via the inhibition of NEDD4L. Frontiers in Cell and Developmental Biology, 8, 620603. https://doi.org/10.3389/fcell.2020.620603

Wang, J.-G., & Yuan, L. (2016). HIF-2α/Notch3 pathway mediates CoCl 2-induced migration and invasion in human breast cancer MCF-7 cells. Sheng li xue bao:[Acta Physiologica Sinica], 68(6), 783-789.

Wang, M., Chen, M.-y., Guo, X.-j., & Jiang, J.-x. (2015). Expression and significance of HIF-1α and HIF-2α in pancreatic cancer. Journal of Huazhong University of Science and Technology [Medical Sciences], 35(6), 874-879. https://doi.org/10.1007/s11596-015-1521-3

Wang, X., Du, Z.-w., Xu, T.-m., Wang, X.-j., Li, W., Gao, J.-l., Li, J., & Zhu, H. (2021). HIF-1α is a rational target for future ovarian cancer therapies. Frontiers in oncology, 11, 785111. https://doi.org/10.3389/fonc.2021.785111

Wang, Y., Liu, Y., Bailey, C., Zhang, H., He, M., Sun, D., Zhang, P., Parkin, B., Baer, M. R., & Zheng, P. (2020). Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin. Oncogene, 39(14), 3015-3027. https://doi.org/10.1038/s41388-020-1201-z

Wang, Y., Shi, J., & Gong, L. (2020). Gamma linolenic acid suppresses hypoxia-induced proliferation and invasion of non-small cell lung cancer cells by inhibition of HIF1α. Genes & Genomics, 42(8), 927-935. https://doi.org/10.1007/s13258-020-00961-5

Wang, Z., Wang, N., Han, S., Wang, D., Mo, S., Yu, L., Huang, H., Tsui, K., Shen, J., & Chen, J. (2013). Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PloS one, 8(7), e68566. https://doi.org/10.1371/journal.pone.0068566

Waring, P., & Beaver, J. (1996). Gliotoxin and related epipolythiodioxopiperazines. General Pharmacology: The Vascular System, 27(8), 1311-1316. https://doi.org/10.1016/S0306-3623(96)00083-3

Warnecke, C., Zaborowska, Z., Kurreck, J., Erdmann, V. A., Frei, U., Wiesener, M., & Eckardt, K. U. (2004). Differentiating the functional role of hypoxia‐inducible factor (HIF)‐1α and HIF‐2α (EPAS‐1) by the use of RNA interference: erythropoietin is a HIF‐2α target gene in Hep3B and Kelly cells. The FASEB Journal, 18(12), 1462-1464. https://doi.org/10.1096/fj.04-1640fje

Wellington, K., & Jarvis, B. (2001). Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs, 15(7), 465-489. https://doi.org/10.2165/00063030-200115070-00005

Wigerup, C., Påhlman, S., & Bexell, D. (2016). Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacology & Therapeutics, 164, 152-169. https://doi.org/10.1016/j.pharmthera.2016.04.009

Wong, B. W., Kuchnio, A., Bruning, U., & Carmeliet, P. (2013). Emerging novel functions of the oxygen-sensing prolyl hydroxylase domain enzymes. Trends in biochemical sciences, 38(1), 3-11. https://doi.org/10.1016/j.tibs.2012.10.004

Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2014). The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. Cancer treatment reviews, 40(4), 558- 566. https://doi.org/10.1016/j.ctrv.2013.10.001

Wu, F., Huang, W., & Wang, X. (2015). microRNA-18a regulates gastric carcinoma cell apoptosis and invasion by suppressing hypoxia-inducible factor-1α expression. Experimental and Therapeutic Medicine, 10(2), 717-722. https://doi.org/10.3892/etm.2015.2546

Wu, Q., You, L., Nepovimova, E., Heger, Z., Wu, W., Kuca, K., & Adam, V. (2022). Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. Journal of hematology & oncology, 15(1), 77. https://doi.org/10.1186/s13045-022-01292-6

Wu, X., Li, M., Li, Y., Deng, Y., Ke, S., Li, F., Wang, Y., & Zhou, S. (2021). Fibroblast growth factor 11 (FGF11) promotes non-small cell lung cancer (NSCLC) progression by regulating hypoxia signaling pathway. Journal of Translational Medicine, 19(1), 353. https://doi.org/10.1186/s12967-021-03018-7

Wu, Y., Dong, L., Bao, S., Wang, M., Yun, Y., & Zhu, R. (2016). FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways. Biomedicine & Pharmacotherapy, 84, 462-469. https://doi.org/10.1016/j.biopha.2016.09.051

Xia, L., Sun, J., Xie, S., Chi, C., Zhu, Y., Pan, J., Dong, B., Huang, Y., Xia, W., & Sha, J. (2020). PRKAR2B‐HIF‐1α loop promotes aerobic glycolysis and tumour growth in prostate cancer. Cell Proliferation, 53(11), e12918. https://doi.org/10.1111/cpr.12918

Xia, Y.-J., Jiang, X.-T., Jiang, S.-B., He, X.-J., Luo, J.-G., Liu, Z.-C., Wang, L., Tao, H.-Q., & Chen, J.-Z. (2017). PHD3 affects gastric cancer progression by negatively regulating HIF1A. Molecular medicine reports, 16(5), 6882-6889. https://doi.org/10.3892/mmr.2017.7455

Xia, Y., Kang, T. W., Jung, Y. D., Zhang, C., & Lian, S. (2019). Sulforaphane inhibits nonmuscle invasive bladder cancer cells proliferation through suppression of HIF-1α-mediated glycolysis in hypoxia. Journal of agricultural and food chemistry, 67(28), 7844-7854. https://doi.org/10.1021/acs.jafc.9b03027

Xiao, Y., Thakkar, K. N., Zhao, H., Broughton, J., Li, Y., Seoane, J. A., Diep, A. N., Metzner, T. J., von Eyben, R., & Dill, D. L. (2020). The m6A RNA demethylase FTO is a HIF-independent synthetic lethal partner with the VHL tumor suppressor. Proceedings of the National Academy of Sciences, 117(35), 21441-21449. https://doi.org/10.1073/pnas.2000516117

Xie, Y.-X., Wang, L., Zhou, Z.-H., Liu, W.-J., Wang, W., Yang, J.-H., He, M.-L., Qiu, J.-G., & Jiang, B.-H. (2024). m6A RNA methyltransferase METTL16 induces Cr (VI) carcinogenesis and lung cancer development through glutamine biosynthesis and GLUL expression. Journal of Hazardous Materials, 480, 136093. https://doi.org/10.1016/j.jhazmat.2024.136093

Xing, F., Okuda, H., Watabe, M., Kobayashi, A., Pai, S. K., Liu, W., Pandey, P. R., Fukuda, K., Hirota, S., & Sugai, T. (2011). Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene, 30(39), 4075-4086. https://doi.org/10.1038/onc.2011.122

Yang, H., Geng, Y.-H., Wang, P., Zhang, H.-Q., Fang, W.-G., & Tian, X.-X. (2022). Extracellular ATP promotes breast cancer chemoresistance via HIF-1α signaling. Cell Death & Disease, 13(3), 199. https://doi.org/10.1038/s41419-022-04647-6

Yang, J., Zhang, X., Zhang, Y., Zhu, D., Zhang, L., Li, Y., Zhu, Y., Li, D., & Zhou, J. (2016). HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer. Journal of Experimental & Clinical Cancer Research, 35(26), 1-10. https://doi.org/10.1186/s13046-016-0298-y

Yang, J., Zhu, D.-M., Zhou, X.-G., Yin, N., Zhang, Y., Zhang, Z.-X., Li, D.-C., & Zhou, J. (2017). HIF-2α promotes the formation of vasculogenic mimicry in pancreatic cancer by regulating the binding of Twist1 to the VE-cadherin promoter. Oncotarget, 8(29), 47801-47815. https://doi.org/10.18632/oncotarget.17999

Yen, L., Benlimame, N., Nie, Z.-R., Xiao, D., Wang, T., Moustafa, A.-E. A., Esumi, H., Milanini, J., Hynes, N. E., & Pages, G. (2002). Differential regulation of tumor angiogenesis by distinct ErbB homo-and heterodimers. Molecular biology of the cell, 13(11), 4029-4044. https://doi.org/10.1091/mbc.e02-02-0084

Ying, L., Zu-An, Z., Qing-Hua, L., Qing-Yan, K., Lei, L., Tao, C., & Yong-Ping, W. (2014). RAD001 can reverse drug resistance of SGC7901/DDP cells. Tumor Biology, 35(9), 9171-9177. https://doi.org/10.1007/s13277-014-1719-1

Yu, B., Li, M.-H., Wang, W., Wang, Y.-Q., Jiang, Y., Yang, S.-P., Yue, J.-M., Ding, J., & Miao, Z.-H. (2012). Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1alpha: a novel function-converter model. Journal of Molecular Medicine, 90(8), 971-981. https://doi.org/10.1007/s00109-012-0865-4

Yu, T., Tang, B., & Sun, X. (2017). Development of inhibitors targeting hypoxia-inducible factor 1 and 2 for cancer therapy. Yonsei medical journal, 58(3), 489-496. https://doi.org/10.3349/ymj.2017.58.3.489

Yu, W., Denu, R. A., Krautkramer, K. A., Grindle, K. M., Yang, D. T., Asimakopoulos, F., Hematti, P., & Denu, J. M. (2016). Loss of SIRT3 provides growth advantage for B cell malignancies. Journal of Biological Chemistry, 291(7), 3268-3279. https://doi.org/10.1074/jbc.M115.702076

Yuan, J., Mo, Y., Zhang, Y., Zhang, Y., & Zhang, Q. (2022). Nickel nanoparticles induce epithelial-mesenchymal transition in human bronchial epithelial cells via the HIF-1α/HDAC3 pathway. Nanotoxicology, 16(6-8), 695-712. https://doi.org/10.1080/17435390.2022.2142169

Yue, H., Liu, L., & Song, Z. (2019). miR-212 regulated by HIF-1α promotes the progression of pancreatic cancer. Experimental and Therapeutic Medicine, 17(3), 2359-2365. https://doi.org/10.3892/etm.2019.7213

Zagzag, D., Lukyanov, Y., Lan, L., Ali, M. A., Esencay, M., Mendez, O., Yee, H., Voura, E. B., & Newcomb, E. W. (2006). Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion. Laboratory Investigation, 86(12), 1221-1232. https://doi.org/10.1038/labinvest.3700482

Zander, S. A., Sol, W., Greenberger, L., Zhang, Y., van Tellingen, O., Jonkers, J., Borst, P., & Rottenberg, S. (2012). EZN- 2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors. PLOS ONE, 7(9), e45248. https://doi.org/10.1371/journal.pone.0045248

Zang, H., Qian, G., Zong, D., Fan, S., Owonikoko, T. K., Ramalingam, S. S., & Sun, S. Y. (2020). Overcoming acquired resistance of epidermal growth factor receptor‐mutant non– small cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589). Cancer, 126(9), 2024-2033. https://doi.org/10.1002/cncr.32744

Zeng, S., Dai, G., Jiang, H., Jia, R., Qin, Q., Liu, Y., Tang, Y., Chen, F., Xu, Y., & Zhang, J. (2025). A phase I dose-escalation study of a first-in-class HIF1 and HIF2 dual inhibitor R01 in patients with advanced tumors. Journal of Clinical Oncology, 43(16-suppl), e15097. https://doi.org/10.1200/JCO.2025.43.16_suppl.e15097

Zeng, Z., Xu, F.-y., Zheng, H., Cheng, P., Chen, Q.-y., Ye, Z., Zhong, J.-x., Deng, S.-j., Liu, M.-l., & Huang, K. (2019). LncRNA-MTA2TR functions as a promoter in pancreatic cancer via driving deacetylation-dependent accumulation of HIF-1α. Theranostics, 9(18), 5298-5314. https://doi.org/10.7150/thno.34559

Zhang, B., Li, Y.-L., Zhao, J.-L., Zhen, O., Yu, C., Yang, B.-H., & Yu, X.-R. (2018). Hypoxia-inducible factor-1 promotes cancer progression through activating AKT/Cyclin D1 signaling pathway in osteosarcoma. Biomedicine & Pharmacotherapy, 105, 1-9. https://doi.org/10.1016/j.biopha.2018.03.165

Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., & Pili, R. (2008). Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proceedings of the National Academy of Sciences, 105(50), 19579-19586. https://doi.org/10.1073/pnas.0809763105

Zhang, J., Culp, M. L., Craver, J. G., & Darley‐Usmar, V. (2018). Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson’s disease. Journal of neurochemistry, 144(6), 691-709. https://doi.org/10.1111/jnc.14308

Zhang, K.-D., Hu, B., Cen, G., Yang, Y.-H., Chen, W.-W., Guo, Z.-Y., Wang, X.-F., Zhao, Q., & Qiu, Z.-J. (2020). MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer. World journal of gastroenterology, 26(19), 2349-2373. https://doi.org/10.3748/wjg.v26.i19.2349

Zhao, Q., Li, Y., Tan, B.-b., Fan, L.-q., Yang, P.-g., & Tian, Y. (2015). HIF-1α induces multidrug resistance in gastric cancer cells by inducing MiR-27a. PloS one, 10(8), e0132746. https://doi.org/10.1371/journal.pone.0132746

Zhao, T., Ren, H., Jia, L., Chen, J., Xin, W., Yan, F., Li, J., Wang, X., Gao, S., & Qian, D. (2014). Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget, 6(4), 2250-2262. https://doi.org/10.18632/oncotarget.2948

Zhao, T., Zhu, Y., Morinibu, A., Kobayashi, M., Shinomiya, K., Itasaka, S., Yoshimura, M., Guo, G., Hiraoka, M., & Harada, H. (2014). HIF-1-mediated metabolic reprogramming reduces ROS levels and facilitates the metastatic colonization of cancers in lungs. Scientific Reports, 4(1), 3793. https://doi.org/10.1038/srep03793

Zheng, Z., Zhou, Z., Zhang, Q., Zhou, X., Yang, J., Yang, M.-R., Zhu, G.-Y., Jiang, Z.-H., Li, T., & Lin, Q. (2021). Non-classical cardenolides from Calotropis gigantea exhibit anticancer effect as HIF-1 inhibitors. Bioorganic Chemistry, 109, 104740. https://doi.org/10.1016/j.bioorg.2021.104740

Zhong, H., Agani, F., Baccala, A. A., Laughner, E., Rioseco- Camacho, N., Isaacs, W. B., Simons, J. W., & Semenza, G. L. (1998). Increased expression of hypoxia inducible factor-1α in rat and human prostate cancer. Cancer Research, 58(23), 5280-5284.

Zhong, H., Chiles, K., Feldser, D., Laughner, E., Hanrahan, C., Georgescu, M.-M., Simons, J. W., & Semenza, G. L. (2000). Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/ PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Research, 60(6), 1541-1545.

Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., Buechler, P., Isaacs, W. B., Semenza, G. L., & Simons, J. W. (1999). Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Research, 59(22), 5830-5835.

Zhong, H., Semenza, G. L., Simons, J. W., & De Marzo, A. M. (2004). Up-regulation of hypoxia-inducible factor 1α is an early event in prostate carcinogenesis. Cancer detection and prevention, 28(2), 88-93.

https://doi.org/10.1016/j.cdp.2003.12.009 Zhou, J., Lan, F., Liu, M., Wang, F., Ning, X., Yang, H., & Sun, H. (2024). Hypoxia inducible factor-1ɑ as a potential therapeutic target for osteosarcoma metastasis. Frontiers in pharmacology, 15, 1350187. https://doi.org/10.3389/fphar.2024.1350187

Zhou, J., Schmid, T., & Brune, B. (2003). Tumor necrosis factor-α causes accumulation of a ubiquitinated form of hypoxia inducible factor-1α through a nuclear factor-κB-dependent pathway. Molecular biology of the cell, 14(6), 2216-2225. https://doi.org/10.1091/mbc.e02-09-0598

Zhou, Q., Liu, L.-Z., Fu, B., Hu, X., Shi, X., Fang, J., & Jiang, B.-H. (2007). Reactive oxygen species regulate insulin-induced VEGF and HIF-1α expression through the activation of p70S6K1 in human prostate cancer cells. Carcinogenesis, 28(1), 28-37. https://doi.org/10.1093/carcin/bgl085

Zhu, H., Wang, D., Zhang, L., Xie, X., Wu, Y., Liu, Y., Shao, G., & Su, Z. (2014). Upregulation of autophagy by hypoxia-inducible factor-1α promotes EMT and metastatic ability of CD133+ pancreatic cancer stem-like cells during intermittent hypoxia. Oncology reports, 32(3), 935-942. https://doi.org/10.3892/or.2014.3298

Zi, X., & Agarwal, R. (1999). Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: implications for prostate cancer intervention. Proceedings of the National Academy of Sciences, 96(13), 7490-7495. https://doi.org/10.1073/pnas.96.13.7490

Ziello, J. E., Jovin, I. S., & Huang, Y. (2007). Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. The Yale journal of biology and medicine, 80(2), 51-60.

Zou, Y., Wang, Z., Jiang, Q., Kong, X., Ma, X., Liang, Z., Wang, Z., Chen, B., Yuan, J., & Wen, J. (2025). UFMylation: A supervisor of the HIF1α pathway and a potential therapeutic target for anti-PD-1 combination therapy in hypoxic tumors. Proceedings of the National Academy of Sciences, 122(27), e2500562122. https://doi.org/10.1073/pnas.2500562122